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As neoplasias de células B são caracterizadas por um grupo 
heterogéneo de doenças que incluem linfomas de células B e 
doenças de células plasmáticas, entre outras. O mieloma múltiplo 
(MM) é uma neoplasia maligna originada pela proliferação de células 
plasmáticas monoclonais que permanece incurável. Esta 
proliferação de células plasmáticas malignas no microambiente da 
medula óssea produz proteína monoclonal no sangue ou na urina e 
está associada a sinais malignos. Representa aproximadamente 1% 
das doenças neoplásicas e 10% a 15% das neoplasias 
hematológicas. O linfoma difuso de grandes células B (DLBCL) é a 
forma mais comum de linfoma não-Hodgkin, representando 31% dos 
linfomas não-Hodgkin, e sendo fatal se não for tratado. DLBCL é um 
linfoma agressivo e de crescimento rápido que pode surgir nos 
gânglios linfáticos ou fora do sistema linfático, no trato 
gastrointestinal, testículos, tiroide, pele, mama, osso ou cérebro. 
A ativação inadequada de vias de sinalização embrionárias, como 
WNT/β-catenina e Hedgehog, vias críticas de autorrenovação das 
células estaminais e diferenciação das células hematopoiéticas, tem 
sido implicada nestas neoplasias de células B. Neste sentido, essas 
vias podem constituir potenciais novos alvos terapêuticos para tratar 
o MM e o DLBCL. 
O objetivo principal deste estudo foi avaliar o potencial terapêutico 
de inibidores das vias WNT/β-catenina e Hedgehog, respetivamente 
IWR-1 e vismodegib, isolados e em combinação um com o outro, 
usando linhas celulares de MM e DLBCL. 
Para avaliar o efeito dos inibidores IWR-1 e vismodegib no MM e 
no DLBCL foram utilizadas linhas celulares H929 (MM) e FARAGE 
(DLBCL), submetidas a diferentes concentrações dos inibidores. A 
atividade metabólica foi avaliada utilizando o ensaio de resazurina, 
a morte celular por microscopia ótica (coloração de May-Grunwald) 
e citometria de fluxo (FC) (marcação com anexina V/7-AAD e 
quantificação de BCL-2 e caspases, proteínas relacionadas com a 
apoptose). A análise do ciclo celular foi avaliada por FC, utilizando a 
solução PI/RNAse. Também por FC, foi avaliada a expressão de β-
catenina e ERK fosforilado, moléculas relacionadas com as vias de 
sinalização WNT/β-catenina e HH. 
 Os resultados mostraram que IWR-1 e vismodegib reduziram a 
atividade metabólica celular de modo dependente do tempo, da linha 
celular e da concentração, em monoterapia ou em combinação. O 
IC50 do IWR-1 nas células H929 e Farage foi de 40 μM e 75 μM, 
respetivamente, enquanto que o IC50 do vismodegib foi de 70 μM 
para as células H929 e 57 μM para as células Farage, após 24 horas 
de tratamento. Estes resultados mostram que as células H929 são 
mais sensíveis ao IWR-1 e, contrariamente, as células Farage são 
mais sensíveis ao vismodegib. Estes compostos induzem a morte 
celular predominantemente por apoptose e induzem bloqueio do 
ciclo celular em G1. 
Em conclusão, os resultados sugerem que IWR-1 e vismodegib 
são potenciais novas terapias direcionadas que poderão ser 
eficientes no tratamento de MM e DLBCL. No entanto, IWR-1 é mais 
indicado para a terapêutica do MM e o vismodegib para a terapêutica 
do DLBCL. 
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abstract 
 
B-cell neoplasms are characterized by a heterogeneous group of 
diseases that include, B-cell lymphomas and plasma cell disorders, 
among others. Multiple myeloma (MM) is a malignant neoplasm 
originated by proliferation of monoclonal plasma cells that remains 
incurable. This clonal proliferation of malignant plasma cells occurs in 
the bone marrow microenvironment, leads to the production of 
monoclonal protein in the blood or urine and is associated with 
malignant signals. It accounts for approximately 1% of neoplastic 
diseases and 10% to 15% of hematologic neoplasms. Diffuse large B-
cell lymphoma (DLBCL) is the most common form of non-Hodgkin 
lymphoma, representing 31% of the non-Hodgkins lymphomas, being 
fatal if untreated. DLBCL is an aggressive, fast-growing lymphoma, 
that can arise in lymph nodes or outside of the lymphatic system, in 
the gastrointestinal tract, testicles, thyroid, skin, breast, bone, or brain.  
Inappropriate activation of conserved embryonic signaling 
pathways, such as WNT/β-catenin and Hedgehog (HH), critical for 
stem cell self-renewal and differentiation of hematopoietic cells, has 
been implicated in these B-cell neoplasms. In this sense, these 
pathways may constitute new potential therapeutic targets to treat MM 
and DLBCL. 
The main goal of this study was to evaluate the therapeutic potential 
of a WNT/ β-catenin and a Hedgehog inhibitor, respectively, the IWR-
1 and vismodegib, alone and in combination, using MM and DLBCL 
cell lines. 
To evaluate the effect of IWR-1 and vismodegib in MM and in 
DLBCL, H929 (MM) and FARAGE (DLBCL) cell lines were submitted 
to different concentrations of the inhibitors. Metabolic activity was 
evaluated using resazurin assay and cell death was evaluated by 
optical microscopy (May-Grunwald staining) and flow cytometry (FC) 
(Annexin V/7-AAD staining and by quantification of BCL-2 and 
caspases expression, apoptosis-related proteins). Cell cycle analysis 
was evaluated by FC, using a PI/RNAse solution. Also by FC the 
expression of β-catenin and phosphorylated ERK, molecules related 
to the WNT/β-catenin and HH signaling pathways, were tested. 
Results showed that IWR-1 and vismodegib reduced cell metabolic 
activity in a time-, cell line- and dose-dependent manner, when 
administrated in monotherapy or in combination. The IC50 of IWR-1 in 
H929 and Farage cells was 40 μM and 75 μM, respectively, and the 
IC50 of vismodegib was 70 μM for H929 cells and 57 μM in Farage 
cells, after 24h of treatment. These results show that H929 cells are 
more sensitive to IWR-1 and, contrarily, Farage cells are more 
sensitive to vismodegib. These compounds induce cell death mainly 
by apoptosis and showed an arrest in cell cycle at G1.  
In conclusion, results suggest that IWR-1 and vismodegib are 
potential new targeted therapies that could be efficient in MM and 
DLBCL treatment in the future. However, IWR-1 is more indicated for 
MM therapy and vismodegib for DLBCL therapy. 
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1. Introduction   
1.1 Cancer 
Cancer is considered a disease of genes. Modifications in genes, such as stimulation of 
oncogenes/proto-oncogenes and/or repression of tumor suppressor genes, confer exclusive 
and advantageous characteristics to the neoplastic cell (1). These cells are characterized by a 
few hallmarks: 1. self-sufficient cell division; 2. insensitivity to signals to stop cell division; 3. 
resisting cell death; 4. limitless reproductive potential; 5. creating their own blood supply; 6. 
invasion and metastasis; 7. ability to survive with little oxygen; 8. immune modulation; 9. 
genomic instability; and 10. inflammation (2). When mutations occur in genes that control 
growth, proto-oncogenes and tumor suppressor genes, cells can grow uncontrolledly, which 
can lead to tumor formation and cancer development (3,4). These changes may result from the 
action of various carcinogenic agents, such as exogenous factors - chemical, physical, and 
biological agents, and/or endogenous factors like inflammation and alteration of the immune 
system. Those agents may induce genetic alterations such as mutations, translocations, 
deletions, and/or amplifications. The human organism has a complex genetic control system, 
which allow the correct dynamic balance between proliferation and cell death. Usually, a self-
destruct mechanism is triggered when a cell becomes senescent or when it is damaged - this 
process is called apoptosis. Therefore, the number of cells in a normal tissue is controlled by 
the balance between cell proliferation and death. Therefore, carcinogenesis, or neoplastic 
transformation, results from the accumulation of non-lethal mutations (tumor initiation 
phase), which may occur over several years or even decades, occurring in certain genes 
responsible for the regulation of the cell cycle (Figure 1) (5). These allows the cells to acquire 
phenotypic characteristics (promotion) that ensure their growth and survival (progression).  
Figure 1 - Multistage process of cancer. Cancer involves the alteration of a cell that becomes a mutated initiated cell 
after DNA synthesis. This initiated cell may clonally grow through either the induction of cell proliferation or the inhibition 
of apoptosis to a focal lesion. Subsequent additional DNA damage and genetic instability may allow selective focal lesions 
to progress to the neoplastic stage. Adapted from (197). 
 
Normal cell Initiated cell Preneoplastic cells Malignant tumor Malignant tumor 
INITIATION PROMOTION PROGRESSION METASTASIS 
DNA repair 
In situ  Differentiated 
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1.2 Hematopoiesis  
There are several different cell types in the blood system with various functions. All these 
blood cellular components are formed by a process named hematopoiesis (6,7). This process 
occurs during embryonic development and throughout adulthood to produce and replace the 
blood system. All blood cells are continuously renewed through the differentiation of a 
common progenitor cell, the hematopoietic stem cell (HSC), localized in the bone marrow (BM), 
the main site of adult hematopoiesis. HSCs have replication and self-renewal capacities, 
allowing some cells to remain in the pluripotent state, while others undergo differentiation. 
The regulation of HSCs maintenance, differentiation and self-renewing processes is effected by 
chemical mediators, including cytokines and chemokines, especially the proteins N-cadherin, 
Notch, Wingless (WNT), Hedgehog, transforming growth factor β (TGFβ), stem cell factor 
(SCF)/c-kit, and fibroblast growth factor (FGF), among others (7). This differentiation process 
leads to the formation of erythrocytes, leukocytes and platelets (Figure 2).  
From the differentiation of hematopoietic stem cells, myeloid and lymphoid progenitor cells 
are formed. The myeloid progenitor cell originates megakaryocytes, erythrocytes, and 
myeloblast, and as this last cell differentiates, it becomes more mature and specialized, 
originating functional blood cells, including neutrophils/ mastocytes, 
monocytes/macrophages, eosinophils, and basophils. In turn, the progenitor cell of the 
lymphoid lineage, the lymphoblast, will originate B and T lymphocytes, and natural killer cells 
(NK). During the differentiation process, HSCs lose their proliferative capacity and increase their 
tendency to cell death by apoptosis. Uncontrolled proliferation, differentiation arrest, and/or 
apoptosis resistance are associated with development and progression of hematologic 
malignancies (6,8).  
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1.3 Hematologic malignancies 
Uncontrolled proliferation, blockade of differentiation and/or resistance to apoptosis are 
mechanisms associated with the development and progression of neoplasms of the 
hematopoietic system (9). These hematologic malignancies are a group of malignant clonal 
diseases that begin in a single bone marrow cell or lymphoid tissue that has undergone genetic 
and/or epigenetic changes. 
Leukemias and lymphomas are the most common hematologic malignancies. They 
represent a group of pathologies that include a great number of distinct entities from the 
biological point of view (10). The World Health Organization (WHO) classification of 
hematopoietic and lymphoid tumors, revised in 2016, is the classification accepted nowadays 
for mature B-cell neoplasms (Table 1) (11). 
Figure 2 - Hematopoiesis representation with important hematopoietic growth factors affecting differentiation. 
Hematopoietic stem cells self-renew and differentiate into specialized cells, multipotent progenitors. These last cells 
differentiate into precursor cells of the myeloid and lymphoid lineage. These will originate the precursors of different blood 
elements, which eventually differentiate into mature blood cells. SCF, Stem cell factor; Tpo, Thrombopoietin; IL, Interleukin; 
GM-CSF, Granulocyte Macrophage-colony stimulating factor; Epo, Erythropoietin; M-CSF, Macrophage-colony stimulating 
factor; G-CSF, Granulocyte-colony stimulating factor; SDF-1, Stromal cell-derived factor-1; FLT-3 ligand, FMS-like tyrosine 
kinase 3 ligand; TNF-a, Tumor necrosis factor-alpha; TGFβ, Transforming growth factor beta. Adapted from  (198). 
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IL-6;  
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Table 1- 2016 World Health Organization (WHO) classification of mature B-cell neoplasms 
Mature B-cell neoplasms  
Chronic lymphocytic leukemia/small lymphocytic lymphoma 
Monoclonal B-cell lymphocytosis 
B-cell prolymphocytic leukemia 
Splenic marginal zone lymphoma 
Hairy cell leukemia 
Splenic B-cell lymphoma/leukemia 
Lymphoplasmacytic lymphoma 
Monoclonal gammopathy of undetermined significance (MGUS) 
Plasma cell myeloma 
Solitary plasmacytoma of bone 
Extraosseous plasmacytoma 
Monoclonal immunoglobulin deposition diseases 
Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue 
(MALT lymphoma) 
Nodal marginal zone lymphoma 
Follicular lymphoma 
Pediatric-type follicular lymphoma 
Large B-cell lymphoma with IRF4 rearrangement 
Mantle cell lymphoma 
Diffuse large B-cell lymphoma (DLBCL), NOS 
Germinal center B-cell type  
Activated B-cell type 
T-cell/histiocyte-rich large B-cell lymphoma 
Primary DLBCL of the central nervous system (CNS) 
Primary cutaneous DLBCL, leg type 
Lymphomatoid granulomatosis 
Primary mediastinal (thymic) large B-cell lymphoma 
Intravascular large B-cell lymphoma 
ALK1 large B-cell lymphoma 
Plasmablastic lymphoma 
Primary effusion lymphoma 
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Burkitt lymphoma 
High-grade B-cell lymphoma, with MYC and BCL2 and/or BCL6 rearrangements 
High-grade B-cell lymphoma, NOS 
B-cell lymphoma, unclassifiable, with features intermediate between DLBCL and 
classical Hodgkin lymphoma 
 Adapted from 2016 revision of World Health Organization classification of lymphoid neoplasms (11). 
 
1.3.1 Multiple myeloma/ Plasma cell Myeloma 
Multiple myeloma (MM) is a malignant neoplasm originated by proliferation of monoclonal 
plasma cells that are derived from a post-germinal-center B cells. This neoplastic disorder 
accounts for approximately 1% of neoplastic diseases and 10% to 15% of hematologic cancers. 
The average age at diagnosis is approximately 70 years with no cases diagnosed in patients 
under 20 years (12,13). Generally, 5-year survival increased from 28.8% to 34.7% (p<0.001), 
and 10-year survival has increased in the last decade mainly due to therapeutic advances 
(13,14). 
MM is usually preceded by an age-dependent pre-malignant tumor named Monoclonal 
Gammopathy of Undetermined Significance (MGUS), present in 1% of adults over the age of 25 
years, and progresses to multiple myeloma or related malignancy a rate of 1% per year (Figure 
3) (15,16). MGUS cells secrete monoclonal immunoglobulin and progress to malignant MM, 
expressing the same immunoglobulin. A study suggests that a preexisting MGUS is present in 
most patients with MM (17,18). The diagnosis of multiple myeloma distinguishes from MGUS 
and requires the presence of one or more myeloma defining events (MDE), in addition to 
evidence of either 10% or more clonal plasma cells on bone marrow examination, or a biopsy-
proven plasmacytoma. MDE consists of established CRAB features (increased calcium levels, 
renal insufficiency, anemia, osteolytic bone lesions) as well as three specific biomarkers of 
maleficence: clonal bone marrow plasma cells ≥60%, serum free light chain (FLC) ratio ≥100 
mg/L, and more than one focal lesion (> 5mm) on magnetic resonance imaging (MRI) (19,20). 
Multiple myeloma can be classified as asymptomatic (smoldering MM) or symptomatic, 
depending on the presence or absence of myeloma-related organ or tissue dysfunction, 
including the referred CRAB symptoms (21–24).  Smoldering myeloma (SMM) implicates a 
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modest proliferation of monoclonal plasma cells, but this proliferation does not interfere with 
physiologic functions of the patient (22). 
Genetic abnormalities change the expression of adhesion molecules on myeloma cells, as 
well as their response to microenvironment growth stimuli. Interactions between myeloma 
cells and bone marrow cells or extracellular matrix proteins that are mediated through  
cell-surface receptors (e.g. integrins, cadherins, selectins, and cell-adhesion molecules) 
increase tumor growth, survival, migration, and drug resistance (25). The adhesion of myeloma 
cells to hematopoietic and stromal cells induces the secretion of cytokines and growth factors, 
including tumor necrosis factors, by cells in the bone marrow microenvironment. 
For symptomatic patients, therapy should be started straightaway. The approach to 
treatment of symptomatic newly diagnosed multiple myeloma is dictated by eligibility for 
autologous stem cell transplantation (ASCT) and risk-stratification (26,27). Induction therapy 
containing agents, such as bortezomib, lenalidomide, and dexamethasone, among other drugs, 
should be administered before transplantation (28–32). Despite these therapies, MM remains 
Figure 3 -  Initiation and progression of multiple myeloma. Monoclonal gammopathy of undetermined significance 
(MGUS) is an indolent, asymptomatic condition that transforms to myeloma at a rate of 1% per annum. Smoldering 
myeloma lacks clinical features; by contrast, symptomatic myeloma has various clinical features that are collectively 
referred to as CRAB, which provide an indication that treatment is required. Later in the disease progression, the 
myeloma plasma cells are no longer restrained to growth within the bone marrow and can be found at extramedullary 
sites and as circulating leukemic cells. It is thought that transition through these different states requires the acquisition 
of genetic abnormalities that lead to the development of the biological hallmarks of myeloma. At the stage of plasma 
cell leukemia the neoplasm is proliferative and no longer confined to the bone marrow; the clone expands rapidly and 
leads to patient death. IGH@, immunoglobulin heavy chain locus. Adapted from (199). 
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incurable (33). Currently, investigational trials are being held to evaluate the ability of others 
immunomodulatory drugs to delay the progression from asymptomatic to symptomatic 
myeloma (16,34,35). Regardless of the major progress that has been made in the treatment of 
MM, most patients relapse. Consequently, new biologically-based treatment strategies are 
urgently needed.  
 
1.3.2 Diffuse large B-cell lymphoma 
Lymphomas are a group of hematological malignancies characterized by accumulation of 
malignant lymphocytes in the lymph nodes. However, they may reach the peripheral blood 
(leukemic phase) or infiltrate other organs. They are subdivided into two major subtypes: 
Hodgkin's Lymphoma (HL) and Non-Hodgkin's Lymphoma (NHL), which behave differently and 
require different treatments (36). NHL originates mainly in B-cells at different stages of 
differentiation, presenting a very variable natural and clinical history.  
Diffuse large B-cell lymphoma (DLBCL) is the most common form of non-Hodgkin lymphoma, 
representing 31% of the NHLs, and it is rapidly fatal if untreated. From a morphological 
standpoint, the 2016 WHO classification defines DLBCL as a diffuse growth of neoplastic large 
B lymphoid cells with a nuclear size equal to or exceeding normal macrophage nuclei (11). Since 
the last decades, its incidence has been increasing in all age groups, except in children, currently 
being 19.5 cases/100,000/year in the United States (37). DLBCL develops from abnormal B cells, 
larger than normal healthy B cells. These abnormal cells are spread diffusely throughout the 
tumor and wipe out the normal structure of the lymph node. DLBCL is an aggressive and  
fast-growing lymphoma that can arise in lymph nodes or outside of the lymphatic system, in 
the gastrointestinal tract, testes, thyroid, skin, breast, bone, or brain (38). Although it can occur 
in childhood, the occurrence of DLBCL generally increases with age, and most patients are over 
the age of 60 at diagnosis, with an expected survival at five years of 50% (10).  
The inherent heterogeneity of DLBCL led to the study of its biology, with focus on whether 
DLBCL could be further subdivided into different categories (39). As DLBCL is a very 
heterogenous disease, it was subdivided in 3 morphologic variants: centroblastic, 
immunoblastic and anaplastic. Amongst these three, the centroblastic variant is the most 
common form. Centroblast, the predominant cell in this form of DLBCL, is a large lymphocyte 
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with a round or oval core, vesicular chromatin, peripheral nucleoli, and basophilic cytoplasm. 
In some cases, the tumor is monomorphic, that is fully composed (more than 90%) by 
centroblasts. In the majority of cases it is polymorphic with a mixture of centroblasts and 
immunoblasts. In the immunoblast variant more than 90% of the cells are immunoblasts, 
immature B lymphocytes with large central nucleus, a single central nucleolus and basophilic 
cytoplasm. The anaplastic variant is characterized, as its name indicates, by the presence of 
rounded, oval or polygonal anaplastic cells, with pleomorphic nucleus and bizarre aspect 
(10,39). The diversity of the DLBCL group is being slowly unraveled and the 2016 WHO 
classification lists a large number of DLBCL sub-groups primarily based on distinct morphologic, 
biologic, immunophenotypic, genetic, or clinical parameters (11). Most DLBCL remains 
biologically heterogeneous and does not fit into any specific disease sub-groups and therefore 
are included in diffuse large B-cell lymphoma, not otherwise specified (DLBCL-NOS) (11,40). 
These NOS cases can be grouped into molecular subtypes of DLBCL that are diagnosed using 
gene expression profiling or testing for protein biomarkers on the surfaces of cancer cells. 
These subtypes are named accordingly to their cell of origin: germinal center B-cell-like (GCB) 
and activated B-cell-like (ABC) (11,41). These groups of patients frequently have different 
prognosis with treatment. Various oncogenic pathways are deregulated in GCB DLBCL that 
contributes to the molecular pathogenesis of this entity. The GCB subtype is associated with 
expression of CD10, BCL6, and BCL2 rearrangements (42). There is a constitutive activation of 
the anti-apoptotic BCL2 protein. The majority of GCB patients are also associated with a better 
prognosis. The ABC subtype associates with MUM1/IRF4 expression, a member of the 
regulatory factor gene family that plays an important role in the regulation of gene expression 
in response to interferon and cytokine, CD5, and CD138 signaling (11,43,44). The majority of 
ABC patients are associated with unfavorable prognosis.  
The regimen of rituximab plus CHOP (cyclophosphamide, doxorubicin, vincristine, and 
prednisone), R-CHOP, has been the standard of care for patients with DLBCL for several years. 
Despite the curability of DLBCL with conventional R-CHOP-based chemotherapy, variability in 
response is often observed, further emphasizing the diversity of this disease (39,45,46).Despite 
the progresses that have been made in the treatment of DLBCL in the last years, most patients 
cannot be cured. Consequently, new treatment strategies are urgently needed. 
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1.4 Cell signaling 
Human cells cannot live isolated, as they need to be in constant communication with other 
cells (47). Communication between cells is crucial for cell differentiation, homeostasis, cell 
growth, and cell interaction. To communicate with each other, cells utilize a complex system of 
mechanisms and cellular signaling pathways that control and coordinate cellular activities and 
functions. These mechanisms allow the cell to induce intracellular signals, from an extracellular 
stimulation. After synthesis and release of the signaling molecule by the cell, the signal is 
transported to the target cell (47,48). There, the signal binds a specific protein receptor, which 
leads to its activation and to the initiation of one or more intracellular signal transduction 
pathways. This induces specific changes in function, metabolism, and development of the cell. 
Finally, the signal is removed, determining the cellular response. 
The normal cell functioning and tissue homeostasis relies on the specific regulation of 
numerous signaling pathways, such as NF-kB, Hedgehog, WNT/β-catenin signaling pathways, 
among others. These pathways control cellular decisions such as proliferation, differentiation, 
cell cycle ending, and possible entry into programmed cell death (apoptosis) (48). Tumors 
originate when cell regulation mechanisms cannot stop mutated cells clones. This leads to 
uncontrolled proliferation without compensatory apoptosis. Several studies defend that the 
deregulation of these signaling pathways is associated with the origin of cancer (48,49). 
Therefore, it is essential to comprehend the normal functioning of these pathways and the way 
they relate to each other, in order to comprehend and synchronize cell grow and apoptosis 
mechanisms. 
Activation of cell signaling pathways terminates in the transcription of genes involved in 
proliferation, differentiation, cell cycle regulation, and apoptosis. In the nucleus, proteins 
known as transcription factors activate genes that drive the cell through the different phases 
of the cell cycle (50). Cell cycle is constituted by four phases: G1 (Gap 1), S (Synthesis), G2 (Gap 
2), and M (Mitosis) phase (Figure 4). In G1 phase, the cells grow in size by synthesis of RNA and 
proteins, and prepares to duplicate the DNA; in S phase, DNA synthesis occurs, with an increase 
in its content; in the G2 phase, the cell prepares for mitosis; and, finally, in the M phase, occurs 
cell division and cytokinesis with the formation of two daughter cells. These daughter cells each 
one restarts a new cycle at G1 phase, and may remain there temporarily or permanently in a 
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non-divisible state (quiescent) designated by G0 phase (4). Cell cycle is regulated by various 
molecules, such as protein phosphatases, CDC (Cell Division Control), tumor suppressor 
proteins such as pRb, p53, p16 and p15 which play an important role in restriction sites 
regulating the cell cycle, and Cyclin/CDK complexes (cyclin dependent kinases), whose 
functions are interdependent (50,51).  
Activation of death pathways, more specifically apoptosis, also involves regulatory 
molecules, activated by mitochondria (intrinsic or mitochondrial pathway) or by death 
receptors (extrinsic or membrane pathway) of the tumor necrosis factor (TNF) family. Binding 
of the ligand to the respective receptors will induce an intracellular response, which will 
subsequently lead to the activation of molecules that are involved in the activation and/or 
inhibition of apoptosis, such as caspases and apoptosis inhibitory proteins, respectively. 
However, the apoptotic process is also regulated by the mitochondria, and different types of 
molecules are involved: those that inhibit apoptosis, like BCL2 protein, or those that induce this 
Figure 4 - Cell cycle phases. In G1 (Gap 1), the cell increases in size, synthesizing proteins necessary for the synthesis of 
DNA that occurs in the next phase, the S phase. The cell can remain in G1, in a non-divisible state, also called the G0 (Gap 
0) phase, or if it decides to continue in a which exceeds the restriction point (R), entering S phase (Synthesis). During this 
phase, the cell doubles its DNA, preparing for mitosis in the G2 phase (Gap 2). In the last phase of the cell cycle, phase 
M (Mitosis) the cell divides into two daughter cells, restarting each of them new cell cycle. Adapted from (50). 
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process as BAX protein. Hence, homeostasis is maintained by the balance between the amount 
of pro- and anti-apoptotic proteins (52,53). 
In the development of embryonic cells and of some adult tissues such as hematopoietic 
tissue, differentiation pathways play a fundamental role. Thus, their deregulation may be 
involved in the development of neoplasms, including in hematopoietic neoplasms. 
 
1.4.1 Differentiation Pathways   
The development and differentiation of human body structures is regulated by complex 
differentiation pathways. These pathways coordinate cell activity, originating the various tissue 
types present in human body. The regulation of hematopoietic stem cells maintenance, 
differentiation, and self-renewing processes is effected by the functioning of proteins from 
Wingless (WNT) and Hedgehog (HH) pathways, among others (54). In this work, it will be 
addressed two pathways involved in the development of organisms involving proteolytic 
cleavage, the WNT and Hedgehog pathways.  
 
1.4.1.1 WNT/ β-catenin Signaling Pathway 
Wingless proteins are part of a family of cysteine-rich glycosylated proteins that contribute 
to lymphopoiesis and early stages of both B- and T- cell development (55). These proteins 
function as extracellular signaling molecules that activate the WNT/β-catenin by binding to the 
extracellular domain of Frizzled receptors and to the low-density lipoprotein receptor-related 
proteins (LRP) 5 and 6 (56). WNT proteins regulate cell proliferation, morphology, motility, and 
fate. WNT signaling activates various intracellular signaling cascades which are associated with 
several forms of cancer (39). Proteins from this signaling pathway can activate three signaling 
pathways: one canonical, WNT pathway - WNT/β-catenin; as well as two noncanonical 
pathways - WNT/Calcium  and WNT/PCP pathway (planar cell polarity) (57). Canonical pathway 
dictates cell fate, while noncanonical WNT pathways control cell movement and polarity.   
In canonical WNT pathway, WNT/β-catenin, under unstimulated conditions (Figure 5A),  
β-catenin is associated in a cytoplasmatic complex with adenomatous polyposis coli (APC) 
Departamento de Química 
Catarina Ferreira 
12 
protein, glycogen synthase kinase-3β (GSK-3β) and axin (56,58). When WNT signaling pathway 
is off-state, in addition to phosphorylating β-catenin, GSK-3β and casein kinase I (CK1) also 
phosphorylate Axin and APC and enhance their binding to β-catenin and degradation complex 
stability, further ensuring β-catenin phosphorylation. This step initiates the phosphorylation 
degradation cascade of β-catenin (59). The phosphorylated β-catenin is recognized by the E3 
ubiquitin ligase subunit β-transducin repeat containing protein (β-TrCP) and targeted for 
ubiquitination and subsequent degradation by the proteasome (58,60). In the presence of WNT 
signaling on-state (Figure 5B), the phosphorylating activity of GSK-3β is inhibited leading to the 
stabilization of β-catenin (61,62). WNT ligand binding to either Frizzed and LRP or to frizzled 
protein alone results in the recruitment of signaling molecules like those members of the 
disheveled (DVL) family are recruited (56,61). Next, axin is dephosphorylated by the protein 
phosphatase 2A (PP2A). This dephosphorylated form of axin binds β-catenin less efficiently, 
promoting the release of β-catenin (63). Unphosphorylated β-catenin accumulates in the 
cytoplasm and is able to translocate into the nucleus (58,64). In the nucleus, β-catenin forms a 
complex with members of the T-cell factor/lymphoid enhancer binding factor (TCF/LEF) family 
of transcriptional factors and then recruits transcriptional co-activators, including cAMP 
response element-binding (CREB)-binding protein (CBP), as well as other components of the 
transcription machinery (64,65). Together, these events transform TCF/LEF from 
transcriptional repressor into transcriptional activator, thereby initiating transcription of WNT 
downstream target genes (66). Any mutations in WNT pathway are, usually, associated with 
congenital abnormalities, cancer, and other diseases (56,67). 
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WNT/β-catenin signaling pathway plays an important role in the proliferation, 
differentiation, and survival of hematopoietic cells. One of the functions of this signaling 
pathway is related to thymocyte and pro-B lymphocytes proliferation, suggesting that WNT 
proteins can function as growth factors of progenitor cells in both B and T lineages (68). 
Overexpression of WNT proteins has been shown to increase proliferation of CD34+ cells, 
making them essential in the process of self-renewal of hematopoietic stem cells (57,69). Due 
to the central function of the WNT pathway in hematopoiesis, the occurrence of some type of 
deregulation in this pathway increases the risk of hematological malignancies (70).  
Figure 5 - Schematic overview of the WNT pathway, without (A) and with (B) WNT activation. In cells not exposed to a 
WNT signal (left panel), β-catenin is degraded through interactions with Axin, APC, and the protein kinase GSK-3. WNT 
proteins (right panel) bind to the Frizzled/LRP receptor complex at the cell surface. These receptors transduce a signal to 
Dishevelled (Dvl) and to Axin, which may directly interact. Consequently, the degradation of β-catenin is inhibited, and this 
protein accumulates in the cytoplasm and nucleus. β-catenin then interacts with TCF to control transcription. APC, 
adenomatous polyposis coli; GSK-3β, glycogen synthase kinase-3β; LRP, lipoprotein receptor-related proteins; DVL, 
dishevelled; TCF, T-cell factor; β-TrCP, β-Transducin repeat containing protein; CKI, casein kinase I; CBP, cAMP response 
element-binding (CREB)-binding protein. Adapted from (200). 
Extracellular 
Intracellular 
Nuclear 
Target genes repressed Target genes activated 
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1.4.1.1.1 WNT signaling pathway as a therapeutic target in multiple myeloma and diffuse large B-cell 
Lymphoma  
The WNT/β-catenin signaling pathway seems to be a promising target in cancer therapy as 
it has been shown to be involved in apoptosis induction, differentiation, and regulation of cell 
proliferation (71). Additionally, aberrant activation of WNT/β-catenin signaling pathway has 
major oncogenic effects, promoting the development of several types of cancer (60,72,73). An 
aberrant activation of WNT pathway with an overexpression of β-catenin has been shown in 
MM and DLBCL, although no known mutations of WNT signaling and β-catenin themselves have 
been reported (55, 62,74–76). Inhibition of WNT/β-catenin signaling pathway results in 
suppressed progression of various hematologic malignancies (77,78). Therefore, the  
WNT/β-catenin signaling molecules are attractive candidates for the development of targeted 
therapies in MM and DLCBL. 
WNT signaling is crucial for the maintenance of osteoblast and osteoclast homeostasis and, 
consequently, coupled bone turnover (79,80). MM is characterized by extensive bone loss and 
osteolytic lesions suggesting that myeloma cells secrete factors that alter the biology of bone 
remodeling. It has been described that multiple WNT receptors and  
co-receptors, like LRP-5 and -6, are expressed specifically in plasma cells of MM patients (55). 
In addition, a β-catenin accumulation in a time-dependent manner in MM cells has been 
observed (55). This translates in an abnormally activation of WNT/β-catenin signaling pathway 
and, consequently, a higher formation of the β-catenin/TCF-regulated transcription complex. 
Cells with active β-catenin/TCF-regulated transcription are protected against apoptosis. In 
opposition, inhibition of canonical WNT signaling activates apoptosis (58,81). A previous study 
of WNT activity in MM demonstrated that nearly all primary MM cells and MM cell lines 
expressed β-catenin, whereas expression was absent in normal plasma cells (74). The 
mechanism activating aberrant β-catenin expression in MM cells is unknown; however, 
expression of β-catenin was associated with transcriptional activity, suggesting that it mediates 
growth of MM cells such as in hematopoietic stem cells (74). Inhibition of WNT signaling 
pathway has been shown to suppress progression of MM. Thus, influencing this pathway could 
be an interesting therapeutic approach (78). In sum, all these studies suggest that inhibiting 
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WNT/β-catenin signaling pathway may be an interesting therapeutic approach in Multiple 
Myeloma. 
Despite the fact that the pathogenesis of DLBCL still remains unknown, a number of 
constitutively activated growth signaling pathways have frequently been observed in DLBCL, 
including nuclear factor κB (NF-κB) and WNT/β-catenin signaling pathways, among others 
(82,83). An overexpression and a mainly nuclear localization of β-catenin in DLBCL was shown, 
an indication of the activation of the WNT/β-catenin pathway (76). Ultimately, the 
overexpression of β-catenin is implicated in the pathogenesis of DLBCL (84).  
In DLBCL, copy number amplifications and chromosomal translocations result in 
overexpression of FOXP1 (Forkhead Box P1) (85). This transcription factor is a master regulator 
of stem and progenitor cell biology (86,87). Increased FOXP1 protein abundance in DLBCL 
predicts poor prognosis and resistance to therapy. A recent study revealed that FOXP1 
potentiates β-catenin-dependent WNT signal transduction. In a WNT-dependent fashion, 
FOXP1 co-complexed with β-catenin, transcription factor 7-like 2 (TCF7L2), and the 
acetyltransferase CBP, and bound the promoters of WNT target genes (85). This study connects 
FOXP1 overexpression with β-catenin-dependent signal transduction and demonstrates that 
the WNT/β-catenin pathway is partly activated in DLBCL and may be associated with the 
pathogenesis of DLBCL.  
 
1.4.1.2 Hedgehog signaling pathway 
Hedgehog signaling pathway is highly regulated and plays a very important role not only in 
the embryonic development but also in tissue formation (organogenesis). Additionally, this 
signaling pathway is essential in tissue reparation and stem cell management in mature tissues 
(88,89). In the adult hematopoietic system, HH signaling regulates T cells’ intrathymic 
development and participates as a mechanism of survival in follicular dendritic cells, thus 
preventing apoptosis in germinal B cells (89,90). Thus, HH signaling pathway has a crucial role 
in both primitive (embryo) and definitive (adult) hematopoiesis (91). There are three ligands 
homologous to the Drosophila gene HH: Sonic hedgehog (SHH), Desert hedgehog (DHH), and 
Indian hedgehog (IHH). These ligands are produced by stromal cells (92). Despite activating the 
same transduction signal, these ligands act in different organs. SHH gene is expressed in central 
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nervous system, lungs, teeth, bowels, and hair follicules; IHH gene is involved in bone condyles 
formation; and DHH gene is mainly expressed in the gonads (90).  
HH signal is transmitted by several key proteins, including PTCH (Patched) and SMO 
(Smoothened), which are found on cell surface (93). PTCH has two homologues in human, 
PTCH1 and PTCH2, and is composed of twelve transmembrane domains. These proteins are 
formed by two extracellular loops, which allow the ligation of HH ligands. In turn, the SMO 
protein is also endowed with intra (homology with GPCRs) and extracellular transmembrane 
domains (94,95). In the absence of HH ligand, PTCH1 inhibits SMO allowing the Glioma 
associated (GLI) processing complex containing Suppressor of fused homolog (SUFU) to 
generate GLIr transcriptional repressors (96). In this situation, GLI proteins are ubiquitinated 
by β-TrCP, a phosphorylation-dependent ubiquitin E3 ligase. Prior to GLI ubiquitination, it is 
required phosphorylation by protein kinase A (PKA), Casein kinase 1 (CK1), and glycogen 
synthase kinase 3β (GSK3β). After ubiquitination, GLI1 is completely degraded and deleted 
from the cell via proteasome, while GLI 2 and 3 are only partially degraded and form low 
molecular weight repressor proteins, which migrate to the nucleus (97–99). 
PTCH1 is initially located in the cilium and SMO is located within cytoplasmic vesicles (Figure 
6). Activating of the signaling pathway by binding of the ligand to the PTCH1 induces 
endocytosis of the PTCH-ligand complex, relieving inhibition of SMO. Consequently, SMO 
migrates to the cilium. There, SMO modulates a cytoplasmic complex containing SUFU that 
modifies the three GLI transcriptional regulators through phosphorylation, sumoylation, and 
selective proteolysis, resulting in the nuclear translocation of the GLI transcriptional regulators 
(100,101). Activation of this signaling pathway occurs in several types of tumors, being involved 
in hematological malignancies, such as multiple myeloma, lymphomas, and chronic myeloid 
leukemia (102).  
The HH signaling pathway has recently been documented to be one of the most important 
signaling pathways and a therapeutic target in cancer. Mutation or deregulation of this 
pathway has a key role in both proliferation and differentiation leading to tumorigenesis or 
tumor growth acceleration in a wide variety of tissues (103–105).  
Universidade de Aveiro 
WNT/β-catenin and Hedgehog signaling pathways as therapeutic targets in B cell neoplasms 
    
17 
1.4.1.2.1 Hedgehog signaling pathway as therapeutic target in multiple myeloma and diffuse large 
B-cell Lymphoma 
In most hematological tumors, HH pathway does not participate in the early events of 
carcinogenesis (102). Instead, it contributes to tumor maintenance, growth, and resistance to 
chemotherapy. Data suggests that, in multiple myeloma, this differentiation pathway 
participates in the expansion and/or survival of cancer stem cells (90,92). Under physiologic 
conditions, HH signaling pathway is under inhibition and is activated upon binding of HH ligand. 
The abnormal HH signaling resulting in new tumors or acceleration of existing tumors could be 
due to: 1. mutation in the HH pathway; 2. paracrine or autocrine activation by HH ligands; 3. 
involvement of stroma; or 4. activation of cancer stem cells (106,107). It has been hypothesized 
Figure 6 - Hedgehog signaling pathway in vertebrates. HH signaling cascade is initiated in the target cell by 
the HH ligand binding to the Patched 1 protein (PTCH1), located on the plasma membrane. Smoothened (SMO) is 
located on the membrane of the intracellular endosome. In the absence of HH ligand, PTCH1 inhibits SMO allowing 
the GLI processing complex containing Suppressor of fused homolog (SUFU) to generate GLIr transcriptional 
repressors. Hedgehog (Hh) ligand binds to PTCH1 which depresses SMO (red cross) and generates GLI1, 2 and 3 
nuclear factors that induce the expression of HH target genes. PKA, protein kinase A; CK1α, Casein kinase 1α; GSK3β, 
Glycogen synthase kinase 3 β. Adapted from (102). 
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that the activation of cancer stem cells through unbalanced HH signaling could be a reason for 
uncontrolled self‑renewal of tumor cells (106).  
The aberrant HH signaling  pathway has been found to be associated with the occurrence of 
basal‑cell carcinoma (108), medulloblastoma (109), multiple myeloma, lymphoma (107), 
diffuse large B-cell lymphoma (110), and some other cancers (111,112). An unusual expression 
of developmental genes from HH pathway has been reported during malignant transformation 
of multiple myeloma cells (113). Several findings support a role of HH signaling regulating the 
stem cell niche in MM  and modulating clinical response to conventional and novel therapeutic 
agents (114,115) A study showed that HH ligands produced by murine bone marrow stromal 
cells (BMSCs) support growth and survival of human primary CD19+ lymphoma and CD138+ MM 
cells, demonstrating a role of HH pathway in lymphoma and terminally differentiated MM cells 
(92). Some data suggested that CD138+ plasma cells from MGUS patients have a significant  
up-regulation of HH-activating genes, such as SMO, PTCH1 and GLI2, compared with CD138+ 
plasma cells from healthy individuals (116). These facts support a role of HH pathway in 
malignant transformation of plasma cells and in the pathogenesis of MGUS. Contrarily, this 
same study reported a significant down-regulation of HH-repressor genes, such as PTCH2 and 
GLI3 in MM plasma cells compared with their normal cellular counterpart. Additionally, MM 
tumor cells overexpress GLI1/GLI2 and PTCH1, suggesting a GLI-dependent HH activation. 
These results are in agreement with recent evidence demonstrating that GLI1 overexpression 
increases MM cells resistance to the antiproliferative effects of the SMO inhibitor cyclopamine 
(114). It was also reported that MM cells display inverse paracrine HH activation, where stromal 
cells produce the HH ligands, which bind and activate this signaling pathway in tumor cells 
(117). 
A study demonstrated that canonical HH signaling pathway regulates the transcription of 
AKT genes, and that AKT1 is a novel direct downstream target of the transcriptional factor GLI1.  
They also  provided  evidence  that  GLI1  contributes  to cell  survival  of  DLBCL  cells  through  
the  expression  of  AKT  in  DLBCL   and   likely   also   in   other   malignant   tumors (118). There 
is biological evidence that HH/GLI signaling pathway plays a role in the pathogenesis of DLBCL 
(119,120). A high expression of breast cancer resistance protein (BCRP, gene symbol ABCG2), a 
member of ATP binding cassette family of transporter proteins, was observed in a subset of 
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DLBCL, additionally to a positive correlation between expression of BCRP and GLI1 (119). Based 
on these studies, it was proved that an elevated activity of the SHH signaling pathway promotes 
DLBCL growth and contributes to chemoresistance in DLBCL. Another study used an Hedgehog 
inhibitor to prove the existence of a role of HH pathway in the pathogenesis of DLBCL (120). 
This HH inhibitor, cyclopamine, suppressed the growth of DLBCL cells, despite increasing their 
expression of GLI1 protein. The explanation for this phenomenon remains to be clarified. The 
suppression of cell growth by cyclopamine implies that HH signaling is constitutively activated 
in those cells. 
 
1.6. IWR-1 and Vismodegib (GDC 0449) 
1.6.1. IWR-1 
The conserved WNT/β-Catenin pathway regulates stem cell pluripotency and cell fate 
decisions during development (121,122). Activation of the WNT receptor complex triggers 
displacement of the multifunctional kinase GSK-3β from a regulatory APC/axin/GSK-3β-
complex. In the presence of WNT ligand, the co-receptor LRP5/6 is brought in complex with 
WNT-bound Frizzled. This leads to activation of DVL by sequential phosphorylation,  
poly-ubiquitination, and polymerization, which displaces GSK-3β from APC/axin through a 
nuclear mechanism that may involve substrate trapping and/or endosome sequestration. 
Stablized β-catenin is translocated to the nucleus, where it binds to TCF/LEF transcription 
factors, displacing co-repressors and recruiting additional co-activators to WNT target genes. 
In the absence of WNT-signal, β-catenin is targeted by coordinated phosphorylation by CK1 and 
the APC/axin/GSK-3β-complex leading to its ubiquitination and proteasomal degradation 
through the β-TrCP/Skp pathway. 
IWR-1, shown in Figure 7, is a WNT/β-catenin signaling pathway inhibitor which suppressed 
WNT signaling by inhibiting accumulation of β-catenin, through promotion of β-catenin 
phosphorylation by stabilizing axin-scaffolded destruction complexes (123). This ability of IWR 
compounds to stabilize axin proteins and induce β-catenin destruction, even in the absence of 
normal APC protein function, suggests that they may block aberrant cell growth supported by 
hyperactivation of WNT/β-catenin responses (123,124). Consistent with the ability of IWR 
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compounds to inhibit cancerous WNT/β-catenin pathway responses, a decrease in the 
expression of axin2 was observed in colorectal cancer cells after exposure to IWR-1 for 2h (124). 
Thus, axin protein stability can be chemically controlled in order to suppress cancerous  
WNT/β-catenin activity, as demonstrated by the IWR compounds.  
 
1.6.2. Vismodegib (GDC 0449) 
The Hedgehog pathway plays a significant role in the development of organs and tissues 
during embryonic and postnatal periods (93,125). The Hedgehog signaling pathway is activated 
upon binding of HH ligand to a PTCH1, a transmembrane receptor, which thereby, decreases 
the inhibitory effects of PTCH1 on SMO (126). This activation allows SMO to transfer signals 
through various proteins and activate an intracellular cascade that results in activation and 
nuclear translocation of GLI family transcription factor GLI2. GLI2 translocates into the nucleus 
and induces the transcription of HH target genes (127,128).  The abnormal HH signaling 
resulting in new tumors or acceleration of existing tumors could be due to mutation in the HH 
pathway, paracrine or autocrine activation by HH ligands, involvement of stroma or activation 
of cancer stem cells (107). Preclinical data suggest that inhibition of the HH pathway via  
small-molecule inhibitors of SMO can lead to decrease in growth and tumorigenesis of human 
pancreatic adenocarcinoma cell lines, as well as prevent distant metastasis from orthotopic 
xenograft cancers in mice (129,130). 
Vismodegib (Figure 8) targets the Hedgehog signaling pathway, blocking the activities of the 
Hedgehog-ligand cell surface receptors PTCH and/or SMO and suppressing Hedgehog signaling 
Figure 7 - IWR-1 Chemical Structure. IWR-1 suppressed WNT signaling by inhibiting accumulation of β-catenin, through 
stabilization of the AXIN2 destruction complex, a negative regulator of canonical WNT signaling. Taken from (201). 
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(131). Therefore, vismodegib is a small-molecule SMO antagonist. In a phase I clinical trial, 68 
patients with solid malignancies refractory to standard therapies were treated with vismodegib 
(132). Tumor responses were observed in 20 (29.4%) patients (19 with basal cell carcinoma) 
and vismodegib was noted to have an acceptable safety  profile. Vismodegib is the first targeted 
inhibitor of the Hedgehog signaling pathway to be approved by the U.S. Food and Drug 
Administration (FDA) (133). Considering these results, vismodegib will be used as a Hedgehog 
pathway inhibitor in MM and DLBCL for the purpose of this work. 
  
Figure 8 - Vismodegib (GDC-0449) chemical structure. Vismodegib blocks the activity of the Hedgehog-ligand cell 
surface receptors PTCH and/or SMO, suppressing Hedgehog signaling. Taken from  (202). 
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 1.5. Objectives 
The present study aimed to investigate the therapeutic potential of a WNT/β-catenin and a 
Hedgehog pathways inhibitor, IWR-1 and vismodegib (GDC 00449), respectively, in Diffuse 
Large B-Cell Lymphoma and Multiple Myeloma cell lines, in monotherapy and in association 
with each other. In addition, the present work aims to clarify the molecular mechanisms 
involved in the cytotoxicity associated with these inhibitors. 
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2 Materials and Methods  
2.1 Cell line characterization  
2.1.1 NCI-H929 [H929] Cell Line 
The NCI-H929 cell line, a multiple myeloma model, was obtained from American Type 
Culture Collection (ATCC). This cell line was isolated from the bone marrow of a 62-year-old 
Caucasian female patient with myeloma (isotype IgA kappa) at relapse. As shown in Figure 9, 
the H929 cells show typical characteristics of malignant plasmocytes as high nucleus/cytoplasm 
ratio, cytoplasmic basophilia, marked nuclear granulations, and binuclearity. These cells are 
round to oval cells and frequently clustered in small clumps in suspension (134). These cells are 
Epson-Barr virus (EBV)-negative and synthesize high amounts of immunoglobulin.  
H929 cell line was grown in culture in Roswell Park Memorial Institute - 1640 (RPMI-1640), 
pH 7 to 7.6, which included 2mM L-Glutamine, 20 mM HEPES-Na, 1.5 g/L NaHCO, 100 μg/mL 
penicillin, 100 μg/mL de streptomycin, and was enriched with fetal bovine serum (FBS) (Gibco, 
Invitrogen) at a concentration of 20%. H929 cells were maintained in culture at a temperature 
of 37 °C in a humid environment with 5% CO2 and an initial cell density of 0.5 million cells/mL. 
The cells were incubated during 96h.  
 
Figure 9 - Morphological aspects of H929 cells. Cell smears were stained with May-Grünwald-Giemsa solution.  
H929 cells show an high nucleus/cytoplasm ratio, cytoplasmic basophilia, marked nuclear granulations. These cells 
are round to oval cells and are frequently clustered in small clumps in suspension (Magnification 500x). 
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2.1.2 Farage Cell Line 
Farage cell line was used as diffuse large B cell non-Hodgkin's lymphoma model, and was 
also obtained from American Type Culture Collection. This cell line was isolated from a 
lymphatic node of an adult Caucasian female patient with non-Hodgkin's B cell lymphoma 
(135). It is a mature B-cell line that grows in suspension, that was immortalized with EBV (136). 
As shown in Figure 10, morphologically, Farage cells are round large cells with at least double 
size of a normal lymphocyte that show small amount of cytoplasm. Farage cells present a 
round-oval nucleus that take up the majority of the cell and present a diffuse growth pattern 
(11). They also present cytoplasmic basophilia and a granular nuclear chromatin. Some of the 
cells form very large closely packed clumps.  
Farage cell line was grown in culture in Roswell Park Memorial Institute - 1640 (RPMI-1640), 
pH 7 to 7.6, which included 2 mM L-Glutamine, 20 mM HEPES-Na, 1.5 g/L NaHCO, 100 U/mL 
penicillin, 100 μg/mL de streptomycin, and was enriched with FBS (Gibco, Invitrogen) at a 
concentration of 20%. Farage cells were maintained in culture at a temperature of 37 °C in a 
humid environment with 5% CO2 and an initial cell density of 0.5 million cells/mL. The cells 
were incubated during 96h. 
 
A B 
Figure 10 - Morphological aspects of Farage cells. Cell smears were stained with May-Grünwald-Giemsa solution. Farage 
cells are round large cells with at least double size of a normal lymphocyte that show small amount of cytoplasm. These 
cells present a round-oval nucleus that take up the majority of the cell. (Magnification 500x (A) and Magnification 1000x 
(B)). 
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2.2 Cell lines’ incubation with IWR-1 and vismodegib 
H929 and Farage cell lines were incubated at the initial cell density of 0.5x106 cells/mL and 
cultured for 96h. Cells were cultured in the absence and presence of the compounds in study: 
IWR-1 (Sigma-Aldrich), a stabilizer of the axin/GS3K complex of the WNT pathway, and 
Vismodegib (GDC 0449, Selleckchem), a SMO antagonist of the Hedgehog pathway. In both cell 
lines, the drug concentrations tested ranged from 1 to 100 μM and 5 to 100 μM, respectively 
for IWR-1 and vismodegib.  
For the study of drug combinations, three combination schemes were tested. Farage cells 
were cultured with 5 μM IWR-1 and 10 μM vismodegib at the same time, 5 μM IWR-1 and 10 
μM vismodegib 3h later, and 10 μM vismodegib and 5 μM IWR-1 3h later. These concentrations 
correspond to concentrations capable of inducing a reduction of approximately 20-25% on cell 
metabolic activity. H929 cells were cultured with 1 μM IWR-1 and 5 μM vismodegib at the same 
time, 1 μM IWR-1 and 5 μM vismodegib 3h later, and 5 μM vismodegib and 1 μM IWR-1 3h 
later. Again, these concentrations were chosen due to its capacity to reduce approximately 20% 
to 25% of cell metabolic activity.  
To study the effect of the fractionated drug administration, doses inducing approximately 
40% of reduction in cell metabolic activity were used. Thus, cells were also incubated with 33 
μM IWR-1 and 46 μM vismodegib (Farage cells) or 13 μM IWR-1 and 18.5 μM vismodegib (H929 
cells), and the same doses divided by four daily administrations individually for 96h of 
incubation. 
 
2.3 Analysis of cell proliferation using a metabolic assay  
Cell metabolic activity studies allow the evaluation of the effects exerted by the inhibitors 
under study (IWR-1 and vismodegib) on different cell lines. To this end the metabolic assay with 
resazurin (Sigma-Aldrich) was conducted, a methodology based on enzymatic reduction of the 
compound by viable cells. The metabolic test with resazurin evaluates survival and proliferation 
by adding a fluorogenic redox indicator to the culture (137,138). Resazurin is the oxidated form, 
with dark blue color, which is converted in resorufin, a high fluorescence form with purple 
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coloration (139). This enzymatic reduction is performed by living cells’ mitochondrial and 
cytoplasmic dehydrogenases and shows a link between fluorescence and cell metabolic 
activity/density. 
Thus, H929 and Farage cells were incubated as described above and cultured in the absence 
and presence of the drugs, at an initial density of 0.5 x 10-6 cel/mL, during 96 hours. Every 24 
hours of incubation, resazurin at 0.1 mg/mL was added to cells at a volume corresponding to 
10% of the volume of cells under study. Then, cells were left to incubate at 37°C with 5% CO2, 
for the time required for the redox reaction to occur. The absorbance was measured at 
wavelengths of 570 nm and 600 nm, on a plate reader spectrophotometer (Synergy™ HT Multi-
Mode Microplate Reader, BioTek Instruments).  
The cell metabolic activity under the effect of the inhibitors in study was calculated using 
the equation depicted below:  
𝑐𝑒𝑙𝑙 𝑚𝑒𝑡𝑎𝑏𝑜𝑙𝑖𝑐 𝑎𝑐𝑡𝑖𝑣𝑖𝑡𝑦 =  
(𝐴570 − 𝐴600)𝑠𝑎𝑚𝑝𝑙𝑒 − (𝐴570 − 𝐴600)𝑤ℎ𝑖𝑡𝑒
(𝐴570 − 𝐴600)𝑐𝑜𝑛𝑡𝑟𝑜𝑙 − (𝐴570 − 𝐴600)𝑤ℎ𝑖𝑡𝑒
 × 100 
In this equation, A570 corresponds to absorbance at 570 nm and A600 to absorbance at 600 
nm wavelength. The results presented represent the mean of three readings and the mean ± 
standard error of the mean (SEM) of at least seven independent experiments. 
 
2.4 Cellular death evaluation 
The distinction of types of cell death induced by the different drugs under study was done 
through analysis of morphological aspects, by optical microscopy, and by flow cytometry using 
double labeling with Annexin V and 7-aminoactinomycin D (7-AAD). 
 
2.4.1 Morphological analysis (May-Grunwald-Giemsa stain) 
H929 and Farage cell morphology was analyzed in the absence and presence of IWR-1 and 
vismodegib for 24h of incubation, by optical microscopy. After incubation, cell smears were 
performed and stained with May-Grunwald-Giemsa (Sigma-Aldrich).  
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To this end, 50000 cells were harvested and centrifuged for 5 minutes at 300 xG. Then, cells 
were washed with phosphate buffer (PBS), by centrifugation at 300 xG for 5 minutes and 
resuspended in 50 µL of FBS, in order to improve cell adhesion to the slide. 
The smears were then stained for three minutes with May-Grünwald solution. This solution 
was prepared in 0.3% methanol and diluted 1: 1 with distilled water, on use. The same quantity 
of water was then added to the smears for one minute. Then, Giemsa's solution (1 g Giemsa 
dye dissolved in 66 ml glycerol and 66 ml methanol, diluted 1: 8 with distilled water, on use) 
was added over 15 minutes. Lastly, the smears were washed and, after drying, the cell 
morphology was analyzed under the optical microscope. The optical microscope used was the 
Nikon Eclipse 80i, coupled with a digital camera, allowing the recording and processing of 
images using the Nikon ACT-1 program.                          
 
2.4.2 Cell Death Evaluation by Flow Cytometry    
Cell death was also analyzed by flow cytometry. In this method, necrosis and apoptosis 
markers were used, such as 7-AAD (BD Biosciences) and Annexin V (BioLegend), respectively. 
Phosphatidylserine is a negatively charged phospholipid normally found in the internal layer of 
the cell membrane (140). In apoptotic cells, there is a change in the phospholipid bilayer, 
especially the translocation of phosphatidylserine to the external layer. Annexin V, when in 
presence of calcium, binds with high affinity to negatively charged phospholipids, such as 
phosphatidylserine, thereby allowing the determination of cells in apoptosis (141). In turn, the 
7-AAD binds selectively to GC regions of DNA, emitting fluorescence. However, 7-AAD entry 
into the cell occurs only when the membrane is disintegrated, this being one of the main 
characteristics of necrotic cells or late stages of apoptosis. By using these two markers, it is 
possible to distinguish viable cells (Annexin V and 7-AAD negative), cells in early apoptosis 
(positive for Annexin V and negative for 7-AAD), cells in necrosis (negative for Annexin V and 
Positive for 7-AAD) and, finally, cells in late apoptosis/necrosis (positive for both compounds). 
In order to evaluate the type of cell death induced by IWR-1 and vismodegib, under the 
respective experimental conditions, the H929 and Farage cells were marked with Annexin V 
and 7-AAD. For this purpose, the equivalent volume of one million cells in cell suspension was 
collected and washed with phosphate buffer (PBS) for 5 minutes at 300 xG. The pellet was 
resuspended in 100 μL of cold binding buffer and then incubated with 2.5 μL of Annexin V-FITC 
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and 5 μl of 7-AAD for 15 minutes in the absence of light as described in the BioLegend's FITC 
Annexin V Apoptosis Detection Kit with 7-AAD. Then, 300 μl of binding buffer were added and 
cells were analyzed on a FACScalibur flow cytometer equipped with an argon laser. The 
excitation wavelengths were 525 nm for the annexin V-FITC and 650 nm for the 7-AAD. Through 
the CellQuest ™ program, 10000 Cells were purchased and the results obtained were later 
analyzed using the Paint-a-GateTM program. The results are presented in percentage of each of 
the cell populations identified on the basis of positivity and/or negativity for double staining 
with Annexin V and/or 7-AAD. 
 
2.4.3 Evaluation of the expression of molecules involved in cell death by flow 
cytometry  
 Evaluation of molecules related to cell death allows the assessment of some of the 
mechanisms involved in the cytotoxic effect induced by the compounds used in this study. 
Through flow cytometry and using monoclonal antibodies labeled with fluorescent probes, 
expression levels of the pro-apoptotic proteins caspases and anti-apoptotic BCL2 were 
analyzed. To this end, approximately half a million cells from the H929 and Farage cells were 
incubated under the conditions mentioned in sections 2.1 and 2.2, and then washed with PBS 
for 5 minutes at 300 xG. Evaluation of intracellular expression of BCL2 proteins requires the 
permeabilization and fixation of cells. According to the instructions of the manufacturer of the 
IntraCell kit (Immunostep), cells were incubated for 15 minutes at room temperature in the 
dark with 50 μL of solution A (fixative solution) (Immunostep). After washing with PBS, the cells 
were again incubated for 15 minutes and in the dark with 50 μL of solution B (permeabilization 
solution) (Immunostep) and with 1 μg of the respective antibody, anti-BCL2 (Santa Cruz 
Biotechnology) labeled with fluorescein isothiocyanate (FITC) (Santa Cruz Biotechnology). The 
cells were then washed again with PBS by centrifugation at 300 xG for 5 minutes. Finally, the 
cells were resuspended in 300 μL of the same buffer. 
Caspase levels were assessed by an intracellular caspase detection kit, ApoStat (R&D 
systems).  In this method, cells undergoing apoptosis are irreversibly labeled with a cell permeable 
inhibitor -  FITC-conjugated pan-caspase inhibitor (ApoStat). Any unbound reagent diffuses out of 
the cell and is washed away. Cells are then analyzed by flow cytometry for the presence of the 
Universidade de Aveiro 
WNT/β-catenin and Hedgehog signaling pathways as therapeutic targets in B cell neoplasms 
    
29 
bound reagent. Increased fluorescence is an indicator of increased caspase activity within cells. 
With this end, cells were washed in 2 ml of PBS by centrifugation at 300 xG for 5 minutes, 
resuspended in 1 ml of PBS, and incubated with 2 μl of ApoStat for 30 minutes at 37°C. The 
cells were then washed again in 2 ml of PBS by centrifugation at 300 xG for 5 minutes and 
resuspended in 300 μl of the same buffer. 
In both cases, detection was performed by flow cytometry using the equipment described 
above in section 2.4.2. The results are expressed as mean fluorescence intensity (MFI) and 
represent the mean expression of the molecules under analysis in the cells under study 
incubated in the absence and presence of the various compounds. The results represent the 
mean ± standard error (SEM) of three independent experiments. 
 
2.5 Evaluation of the inhibition of the WNT/ β-catenin and Hedgehog signaling 
pathways 
2.5.1 Intracellular evaluation of β-catenin and p-ERK expression 
In order to evaluate the action of IWR-1 and vismodegib in the targeted signaling pathways, 
expression of β-catenin, a target molecule in WNT/β-catenin signaling pathway, and ERK, a 
molecule activated by Hedgehog signaling pathway (142), was evaluated. Thus, Farage and 
H929 cells were incubated in the conditions described in sections 2.1 and 2.2, and, 
approximately, 0.5 million cells were washed by centrifugation with PBS pH=7.4 for 5 minutes 
at 300 xG. Then, the cell suspensions were incubated for 15 minutes at room temperature in 
the dark, with 50 μL of fixation solution (Immunostep). After washing, cells were incubated in 
50 μL of permeabilization solution (Immunostep) and 5 μL of antibody mouse monoclonal  
β-catenin (Santa Cruz Biotechnology) for 15 minutes in the dark. Cells were washed with PBS 
and incubated with 2.5 μl of secondary antibody chicken anti-mouse (Santa Cruz 
Biotechnology) for 30 minutes in the dark. Then, cells were washed again with PBS and 
centrifugation at 300 xG for 5 minutes, and incubated in 5 μl of p-ERK FITC (Santa Cruz 
Biotechnology). Finally, cells were washed by centrifugation at 300 xG for 5 minutes and 
resuspended in 300 μl of the same buffer. The results are expressed in MFI and represent the 
mean intracellular expression of β-catenin in the cells under study incubated in the absence 
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and presence of IWR-1 and vismodegib. The results represent the mean ± SEM of three 
independent experiments.  
2.6 Cell cycle evaluation 
In order to assess the antiproliferative effect of IWR-1 and vismodegib, the distribution of 
cells by the different phases of the cell cycle, G0/G1, S and G2/M, was analyzed by flow 
cytometry using a propidium iodide and RNase (PI/RNase) solution (Immunostep). 
To this end, the cells were incubated under the conditions previously described at sections 
2.1 and 2.2 and washed with PBS by centrifugation at 300 xG for 5 minutes. Then, it was added 
200 μl of cold 70% ethanol and incubated for 30 minutes at 4˚C, in order to fixate cells. After 
this incubation period, cells were washed similarly to before. Then, by centrifugation cells were 
resuspended and incubated in 300 μl of the PI/RNASE solution (Immunostep) for 15 minutes in 
the dark. The results were analyzed using the Mod-FITTM program and represent the percentage 
of cells in each phase of the cell cycle. The results represent the mean ± standard error of three 
independent experiments. 
 
2.7 Statistical analysis 
The statistical treatment of the results was performed using the GraphPad Prism 6 software, 
version 6.01. In the analysis of metabolic activity curves, Kruskall-Wallis test was used, except 
for fractionated administration, where T-test was used. In the cytometry analysis, one-way 
ANOVA test was used, due to the Gaussian distribution of the results. A level of statistical 
significance of 95% (p<0.05) was considered for all the tests. The results are presented as mean 
± standard error.  
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3 Results 
3.1 Effect of IWR-1 and vismodegib on H929 and Farage cell proliferation and 
death 
Knowledge of key signaling pathways and proteins involved in the apoptotic process 
provides the possibility of using new drugs targeting these molecular targets. In this sense, two 
distinct compounds were used, namely IWR-1, a WNT/β-catenin pathway inhibitor, and 
vismodegib, a Hedgehog pathway inhibitor. The changes in metabolic activity induced by these 
drugs in H929 and Farage cells were evaluated through the resazurin assay. The type of cell 
death induced by the different inhibitors was evaluated by flow cytometry using the double tag 
annexin V/ 7AAD, and by the evaluation of the morphological changes by optical microscopy. 
 
3.1.2 Metabolic activity curves  
In order to determine the therapeutic potential of the WNT inhibitor, IWR-1, and the 
Hedgehog inhibitor, vismodegib, the metabolic activity of H929 and Farage cells was assessed 
by the resazurin assay. To this end, H929 and Farage cells were incubated in the absence 
(Control) and presence of crescent concentrations of compounds in study (1 to 100 µM for 
IWR-1 and 5 to 100 µM for vismodegib) during 96 hours, either alone or in combination with 
each other. Dose-response curves of IWR-1 and vismodegib in H929 and Farage cells are 
represented in Figure 11 and 12, respectively.  
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As observed in Figure 11, as early as 24h, there is a dose- and cell type-dependent effect 
induced by IWR-1 in both H929 and Farage cells. IWR-1 induces a reduction of metabolic 
activity after 24 hours of incubation, being the IC50 of approximately 40 μM at 24h and between 
10 μM to 40 μM at 96h of incubation, for H929 cells. Farage cells require 75 μM and 50 μM to 
75 μM of IWR-1, at 24h and 96h respectively, in order to reduce cell metabolic activity by 50%. 
In sum, it can be said that Farage cells require higher doses of IWR-1 to induce an alteration in 
B 
Figure 11 - Effect of IWR-1, the WNT/β-catenin inhibitor, on metabolic activity of H929 (A) and Farage (B) cells. 
Cells were incubated at an initial density of 0.5x10 6 cells/mL, in the absence (control) and in the presence of 
increasing concentrations of the WNT inhibitor, for 96 hours. Cell metabolic activity were evaluated using the 
resazurin assay as described in materials and methods. The results represent the mean ± SEM of seven 
independent experiments. 
A H929 
Farage 
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metabolic activity similar to that observed in H929 cells, being the last ones more sensitive to 
IWR-1. For doses equal to or greater than 50 µM, it can also be observed a time of exposure-
dependent effect in H929 and Farage cells. Through the 96h of incubation, metabolic activity is 
reduced to less than 50% for concentrations of 50 μM and 75 μM of IWR-1 in H929 cells 
(p<0.001). At 96h of incubation with IWR-1, H929 cells showed a significant reduction of 
metabolic activity for concentration of 30 μM and concentration equal to or greater than 50 
μM (p<0.01). In Figure 11B, it can be seen at 24h in Farage cells, a significant reduction in 
metabolic activity in concentration of IWR-1 equal to or greater than 20 μM (p<0.05). From all 
the concentrations used in Farage cells, those equal to or greater than 50 μM induce a 
reduction on metabolic activity of more than 50% (p<0.01). At 96h of incubation, only 
concentrations equal to or greater than 30 μM can be considered different from Farage cells 
with no treatment with IWR-1 (p<0.01). For some IWR-1 concentrations, a slightly reversion of 
effect was also observed after 96h of incubation in both H929 and Farage cells.  
In Figure 12A, it can be observed that H929 cells treated with vismodegib showed a 
reduction of metabolic activity of more than 50% for concentrations equal to or greater than 
75 μM (p<0.01) at 24h of incubation. At 96h of incubation, H929 cells show a significant 
reduction of metabolic activity for concentrations equal to or greater than 25 μM vismodegib 
(p<0.05). Under vismodegib inhibition, Farage cells present a reduction in metabolic activity to 
50% or less for concentrations equal to or greater than 57 μM throughout the incubation 
(p<0.01) (Figure 12B). Thus, in H929 cells treated with vismodegib the IC50 was reached 
approximately at a concentration between 50 μM and 75 μM at 24h of incubation and between 
25 μM and 70 μM at 96h of incubation. In the Farage cells treated with vismodegib, the IC50 
was between 57 μM and 75 μM at 24 and 96 hours of incubation. Althought Farage cells present 
a earlier effect to the vismodegib-induced cell death, at 96h of incubation, H929 cells require 
lower doses than Farage cells, thus being more sensitive to vismodegib. In H929 and Farage 
cells can also be observed a dose- and cell type-dependent effect induced by vismodegib. 
Additionally, for doses equal to or greater than 75 µM, it can be observed a time of exposure-
dependent effect in H929 cells.  For some vismodegib concentrations, a slightly reversion of 
effect was also observed after 96h of incubation in both H929 and Farage cells. 
When treating patients with conventional anticancer drugs, there are usually side effects 
arising from the high doses used in the therapeutic schemes, which may also be influenced by 
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the selected mode of administration. Thus, it was assessed whether the mode of administration 
of IWR-1 and vismodegib had influence on the cell metabolic activity previously observed. 
These compounds were added to the cell culture in daily administration, every 24 hours of 
incubation, at lower concentrations than those used in the single dose scheme, corresponding 
Figure 12- Effect of vismodegib (GDC), the Hedgehog inhibitor, on metabolic activity of H929 (A) and Farage (B) 
cells. Cells were incubated at an initial density of 0.5x10 6 cells/mL, in the absence (control) and in the presence of 
increasing concentrations of the HH inhibitor, for 96 hours. Cell metabolic activity were evaluated using the resazurin 
assay as described in materials and methods. The results represent the mean ± SEM of seven Independent experiments. 
GDC, vismodegib 
H929 
Farage 
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to a concentration capable of inducing approximately 30% to 40% cell death in H929 and Farage 
cells (Figure 13 for IWR-1 and Figure 14 for vismodegib). 
As observed in Figure 13A, daily administration of 3.3 μM IWR-1 to H929 cells, for 96 hours, 
induces a greater reduction of cell metabolic activity than that observed when cells are treated 
with the same single administration concentration (13 μM) (p<0.001). In Figure 13B, the same 
effect can also be seen in Farage cells with the daily administration of 8.3 μM IWR-1 versus the 
single administration of 33 μM IWR-1 (p<0.05). The metabolic activity alterations induced by 
Figure 13 - Effect of daily administration of IWR-1, WNT/β-catenin inhibitor, on metabolic activity of H929 (A) and 
Farage (B) cells. Cells were incubated at an initial density of 0.5x10 6 cells/mL, in the absence (control) and in the 
presence of IWR-1, for 96 hours, and analyzed by resazurin assay. In (A) the H929 cell metabolic activity under IWR-
1 is shown, with two different concentrations, one of which is administered daily, while in (B) the cell metabolic 
activity under IWR-1 in Farage cells is verified. The results represent the mean ± SEM of seven independent assays. 
H929 
Farage 
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daily doses of IWR-1 are shown to be more noticeable in H929 cells than in Farage cells, even 
at a lower administered dose (3.3 μM versus 8.3 μM). 
Figure 14 shows that daily administration of vismodegib to H929 would be a more effective 
therapeutic strategy than single dose administration. The daily administration of 4.6 μM 
vismodegib induces a lower metabolic activity than that observed at 18.5 μM vismodegib 
(single dose administration) after 96h of incubation in H929 cells, indicating that this 
therapeutic regimen may be more effective in this type of modulators (p<0.01). In Figure 15B, 
it can be observed that the daily dose of 11.5 μM vismodegib induced approximately the same 
Figure 14 -  Effect of daily administration of vismodegib (GDC), Hedgehog inhibitor, on metabolic activity of H929 
(A) and Farage (B) cells. Cells were incubated at an initial density of 0.5x10 6 cells/mL, in the absence (control) and in 
the presence of vismodegib, for 96 hours, and analyzed by resazurin assay. In (A) the H929 cell metabolic activity under 
vismodegib is shown, with two different concentrations, one of which is administered daily, while in (B) the cell 
metabolic activity under vismodegib in Farage cells is verified. The results represent the mean ± SEM of seven 
independent assays. 
H929 
Farage 
Universidade de Aveiro 
WNT/β-catenin and Hedgehog signaling pathways as therapeutic targets in B cell neoplasms 
    
37 
reduction in metabolic activity compared with the single dose 46 μM vismodegib in Farage cells. 
Similarly to what happens with daily administration of IWR-1, H929 cells are also more sensitive 
to daily therapy with vismodegib (4.6 μM) than Farage cells (11.5 μM).   
Cancer patients are often treated with therapeutic regimens that include various anti-cancer 
drugs. With this purpose, it was studied whether the combination of the two modulators of cell 
signaling pathways, IWR-1 and vismodegib, could induce a more pronounced reduction of cell 
metabolic activity. In addition, the use of low concentrations of these inhibitors, concentrations 
lower than the IC50 in monotherapy, may potentially induce lower side effects. To this end, 
after the tests with the different drugs in monotherapy, the H929 and Farage cells were 
incubated in the absence and the presence of IWR-1 and vismodegib, in simultaneous 
administration and with a 3-hour difference between the administration of the two inhibitors. 
As noted in Figure 15, H929 cells treated with the combination of 5 μM vismodegib and 1 
μM IWR-1, independently of the mode of administration, present a significant reduction in 
metabolic activity to values close to 60%, after 96 hours of incubation (p<0.05) in comparison 
to IWR-1 and vismodegib in monotherapy. The simultaneous combination of the two 
compounds induces an additive effect in the reduction of metabolic activity in H929 cells. 
Likewise, it has been found that the additive effect is independent of administration scheme, 
i.e., if it is first administered IWR-1 and after 3 hours vismodegib or vice versa. At 96h of 
Figure 15 - Effect of the combination of the IWR-1 and vismodegib (GDC) on metabolic activity of H929 cells. Cells 
were incubated at an initial density of 0.5x10 6 cells/mL, in the absence (Control) and in the presence of IWR-1 and 
vismodegib, for 96 hours, and analyzed by resazurin assay. In this graph is shown the combination of the two modulators 
under study, administrated simultaneously or with a 3-hour difference, as well as the used concentrations individually. 
The results represent the mean ± SEM of seven independent experiments. GDC, vismodegib 
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incubation, the simultaneous administration of both inhibitors induces a significant decrease 
in cell metabolic activity, compared with the monotherapy with either inhibitors (p<0.01). In 
Farage cells (Figure 16) the additive effect of the therapeutic association was much more 
evident at 96h of incubation. The individual administration of 5 μM IWR-1 and 10 μM 
vismodegib in monotherapy induced a reduction to approximately 70% of cell metabolic 
activity, while the combination of both inhibitors showed a reduction of cell metabolic activity 
to approximately 40%. Although no significant difference was observed at 24h, at 96h of 
incubation, all combination schemes induced a significant decrease in cell metabolic activity, 
compared with the monotherapy with either inhibitors (p<0.05). There was no significant 
difference between the three combination schemes of IWR-1 and vismodegib in Farage cells. 
  
3.1.3 Cell death analysis by flow cytometry 
The cytotoxic effect of IWR-1 and vismodegib on the H929 and Farage cells was assessed by 
analysis of the cell death type, by flow cytometry using the Annexin V/7-AAD double-staining, 
allowing to discriminate between viable cells and nonviable cells through change in membrane 
permeability and composition, allowing the identification of cell death mechanism induced by 
IWR-1 and vismodegib: apoptosis or necrosis.  
Figure 16 - Effect of the combination of the IWR-1 and vismodegib (GDC) on metabolic activity of Farage cells. Cells 
were incubated at an initial density of 0.5x10 6 cells/mL, in the absence (Control) and in the presence of IWR- 1 and 
vismodegib, for 96 hours, and analyzed by resazurin assay. In this graph is shown the combination of the two 
modulators under study, administrated simultaneously or with a 3 hour difference, as well as the used concentrations 
individually. The results represent the mean ± SEM of seven independent experiments. GDC, vismodegib 
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In Figure 17, it is possible to observe that both IWR-1 and vismodegib compounds induce 
cell death mainly by apoptosis. Cell percentage in apoptosis and/or necrosis depended on 
Figure 17 - Evaluation of death cell induced by IWR-1 and vismodegib (GDC) on H929 (A) and Farage (B) cells by flow 
cytometry. H929 and Farage cells were incubated at an initial density of 0.5x106 cells/mL, in the absence (Control) and in 
the presence of IWR-1 and vismodegib with the concentration indicated in the legend, for 24 hours. Lately, the cells were 
labeled with Annexin V/ 7-AAD, as described in methods section, allowing to distinguish between percentage of living cells, 
cells in initial apoptosis, late apoptosis/necrosis and necrosis. The results are expressed as a percentage (%) and represent 
the mean ± SEM of three independent experiments. The statistical analysis was performed by comparison with the control, 
using the One-way ANOVA test. 40 µM IWR-1 and 75 µM IWR-1 correspond to IC50 doses for H929 and Farage cells.  70 
µM GDC and 57 µM GDC correspond to IC50 doses for H929 and Farage cells. 1 µM IWR-1 + 5 µM GDC and 5 µM IWR-1 + 
10 µM GDC correspond to combination therapy for H929 and Farage cells. ** p <0.01 and *** p <0.001, comparing with 
control; $ p<0.5 and $$$ p<0.001, comparing with 1 μM IWR-1 and 5 μM vismodegib. GDC, vismodegib. 
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inhibitors concentration and cell line. However, IC50 doses of IWR-1 and vismodegib at 24h of 
incubation (40 μM IWR-1 and 70 μM vismodegib for H929 cells; 75 μM IWR-1 and 57 μM 
vismodegib for Farage cells) induced cell death preferentially by late apoptosis/necrosis 
(annexin V positive and 7-AAD positive).  
The cytotoxic effect of therapeutic combinations was also assessed by flow cytometry 
(Figure 17). Since simultaneous combination shown no differences compared to the other 
combination schemes, flow cytometry assays were carried out in simultaneous administration. 
The results obtained show that when IWR-1 and vismodegib are associated, there is an increase 
in the percentage of cell death by apoptosis, compared to the use of the two inhibitors in 
monotherapy. These results can be observed in both cell lines, H929 and Farage.  
 
3.1.4 Cell death analysis by cellular morphology  
The cytotoxic effect induced by IWR-1 and vismodegib was also characterized by cell 
morphology using optical microscopy in the absence and presence of these compounds. Figure 
18 shows the characteristic morphological features of the cytotoxic effects induced by IC50 
concentrations of IWR-1 and vismodegib on H929 and Farage cells.  
As shown in Figure 18, H929 and Farage cells treated with IC50 doses of IWR-1 and 
vismodegib (70 µM vismodegib and 40 µM IWR-1 for H929 cells; and 57 µM vismodegib and 75 µM 
IWR-1 for Farage cells) in monotherapy, had typical morphological characteristics of cell death 
mediated by apoptosis. Both cell lines treated with IWR-1 and vismodegib showed cellular 
contraction, nuclear fragmentation, various cytoplasmic projections (blebbing) and 
vacuolization, which is in agreement with the previous results obtained by flow cytometry. 
Similar characteristics were also observed in Figure 19, when H929 and Farage cells were 
treated in the presence of monotherapy with 1 μM IWR-1 or 5 μM vismodegib, in H929 cells, 
and of IWR-1 at 5 μM or vismodegib at 10 μM, in Farage cells. In combination therapy, Farage 
and H929 cells also showed typical morphological characteristics of apoptosis, namely cell 
nuclear contraction, presence of projections of the cytoplasmic membrane, nuclear division 
and chromatin condensation. 
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Figure 18 - Morphological aspects of H929 and Farage cells without treatment and with treatment with IC50 
concentrations of IWR-1 and vismodegib (GDC). The cell lines under study were incubated at an initial density of 
0.5x106 cells/ml in the absence (control) and in presence of 70 µM vismodegib and 40 µM IWR-1, for H929 cells; 57 
µM vismodegib and 75 µM IWR-1, for Farage cells. After a 24-hour incubation period, cell smears were stained with 
May-Grünwald-Giemsa staining as described in the material and methods section. Cells were observed under an 
optical microscope at a magnification of 500x. GDC, vismodegib 
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Figure 19 - Morphological aspects of H929 and Farage cells in the absence of treatment and with treatment with 
combination doses of vismodegib (GDC) and IWR-1. The cell lines under study were incubated at an initial density of 
0.5x106 cells/ml in the absence (control) and in presence of monotherapy with 5 µM vismodegib or 1 µM IWR-1, in H929 
cells; and 10 µM vismodegib or 5 µM IWR-1, in Farage cells, and in presence of a combination scheme with IWR-1 1 µM 
+ GDC 5 µM or IWR-1 5 µM + GDC 10 µM, respectively for H929 and Farage cells.  After a 24-hour incubation period, 
cell smears were stained with May-Grünwald-Giemsa as described in the material and methods section. Cells were 
observed under an optical microscope at a magnification of 500x. GDC, vismodegib. 
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3.2 Influence of IWR-1 and vismodegib on the expression of molecules involved in 
cell death by apoptosis 
 
In order to clarify some mechanisms involved in apoptosis induced by IWR-1 and vismodegib 
in H929 and Farage cells, the expression of molecules involved in the regulation of cell death 
by apoptosis was evaluated, namely caspases and BCL2. As observed in Figure 20A, H929 cells 
treated with 40 μM IWR-1 (IC50 at 24h) and those treated with 70 μM vismodegib (IC50 at 24h) 
had a significant increase in the percentage of cells expressing activated caspases, compared 
Figure 20 - Evaluation of intracellular expression levels of activated caspases in the H929 cells exposed to IWR-1 
and vismodegib (GDC) by flow cytometry. Cells were incubated for 24 hours with the two inhibitors, individually and 
in combination. In (A) is represented the percentage of cells expressing activated caspases and in (B) is represented 
the expression levels of activated caspases in mean fluorescence intensity (MFI). The results represent the mean ± 
SEM of three independent experiments. The statistical analysis was performed by comparison, using the One-way 
ANOVA test, being ** p <0.01 and ***p<0.001.  40 µM IWR-1 and 70 µM GDC correspond to IC50 doses for H929 cells.  
1 µM IWR-1 + 5 µM GDC correspond to combination therapy doses. GDC, vismodegib 
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with control. However, no significant differences were observed in the expression levels of 
activated caspases (Figure 20B). Furthermore, the induction of activated caspases by the 
combination scheme (1 μM IWR-1 + 5 μM vismodegib) was not significantly different from the 
observed in monotherapy.  
Farage cells treated with 75 μM IWR-1 (IC50 at 24h of incubation) and those treated with 57 
μM vismodegib (IC50 at 24h of incubation) had a significant increase in percentage of cells 
expressing activated caspases, compared to control (Figure 21A). When cell were treated with 
Figure 21 - Evaluation of intracellular expression levels of activated caspases in the Farage cells exposed to IWR-1 
and vismodegib (GDC) by flow cytometry. Cells were incubated for 24 hours with the two inhibitors, individually and 
in combination. In (A) is represented the percentage of cells expressing activated caspases and in (B) is represented 
the expression levels of activated caspases in mean fluorescence intensity (MFI). The results represent the mean ± 
SEM of three independent experiments. 75 µM IWR-1 and 57 µM GDC correspond to IC50 doses for Farage cells. 5 µM 
IWR-1 + 10 µM GDC correspond to combination therapy doses. The statistical analysis was performed by comparison, 
using the One-way ANOVA test, being ** p <0.01 and ***p<0.001. GDC, vismodegib 
Universidade de Aveiro 
WNT/β-catenin and Hedgehog signaling pathways as therapeutic targets in B cell neoplasms 
    
45 
the combination scheme 1 μM IWR-1 + 5 μM vismodegib, they expressed a higher number of 
activated caspases when compared with cells treated with the drugs in monotherapy. 
However, in Figure 21B, it can be observed that there was no significant difference in the 
expression levels of activated caspases in cells treated with 75 μM IWR-1, except when cells 
were treated with 57 μM of vismodegib. There is no significant difference in the expression 
levels of activated caspases between cells incubated with the combination scheme and the 
monotherapy scheme. In general, comparing Figure 20 with Figure 21, it can be observed that 
Farage cells, when treated with IWR-1 and/or vismodegib, express a higher number of activated 
caspases when compared to H929 cells.  
In addition to the activated caspase levels, the effect of IWR-1 and vismodegib on the 
expression levels of BCL2 protein was also evaluated. As showed in Figure 22A, despite a slight 
decrease in anti-apoptotic protein BCL2 expression in the various conditions tested in H929 
cells when compared to control, there was no statistical significant difference. However, in 
Farage cells, treated with vismodegib at 57 μM there was a significant decrease of BCL2 
expression levels. 
 
3.3 Effect of IWR-1 and vismodegib on the cell cycle 
Many signaling pathway modulators have an antiproliferative effect by activating cell 
checkpoints inducing cell cycle arrest, being recognized as cycle-dependent. To characterize 
the effect of IWR-1 and vismodegib on the cell cycle distribution of H929 and Farage cells, DNA 
content was analyzed by flow cytometry after cell labeling with Propidium Iodide/RNAse, as 
described in the material and methods section. 
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Table 2 shows the distribution of H929 and Farage cells by the different phases of the cell 
cycle, in the absence and presence of the anticancer compounds. H929 and Farage cells were 
mainly in the G0/G1 phase in the absence of treatment. When cells are incubated in the 
presence of IWR-1 and vismodegib, a slight increase in the percentage of cells in the G0/G1 
phase was observed when compared to control cells (H929: Control 64.33±0.88%; 40 µM IWR-
1 73.00±0.58%, p=0.0056; 70 µM vismodegib 77.67±0.67%, p=0.0002; Farage: Control 
54.67±1.67%; 75 μM IWR-1 65.67±1.86%, p=0.0010; 57 µM vismodegib 70.33±0.33%, 
Figure 22 - Evaluation of intracellular expression of BCL2 in H929 and Farage cells treated with IWR-1 and vismodegib 
(GDC) by flow cytometry.  Intracellular expression of BCL2 in the absence and in the presence of IWR-1 and vismodegib 
at the concentrations observed in the legend, was evaluated after 24 hours of incubation by flow cytometry, using 
monoclonal antibodies as described in materials and methods. The results are expressed as mean intensity of 
Fluorescence (MFI) and represent the mean ± SEM of three independent experiments. 40 µM IWR-1, 75 µM IWR-1,70 
µM GDC, and 57 µM GDC correspond to IC50 doses for H929 and Farage cells. 1 µM IWR-1 + 5 µM GDC and 5 µM IWR-
1 + 10 µM GDC correspond to combination therapy doses for H929 and Farage cells. The statistical analysis was 
performed by comparison, using the ONE-WAY ANOVA. ** p <0.01. GDC, vismodegib 
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p=0.0001). When cells were incubated with the therapeutic combination scheme, there is a 
slight increase in the percentage of cells in sub-G0/G1 (apoptotic peak) (H929: Control 
2.67±0.88%, 1 µM IWR-1 + 5 µM vismodegib 8.33±1.76%; Farage: Control 1.33±0.33%, 5 µM 
IWR-1 + 10 µM vismodegib 7.00±1,53%). In H929 cells, the number of cells in G0/G1 and S 
phases was only significantly higher than in monotherapy with IWR-1 1 µM but not significantly 
different from monotherapy with vismodegib 5 µM. 
 
Table 2-Influence of IWR and vismodegib inhibitors on the distribution of Farage and H929 cells by the different 
phases of the cell cycle. 
 
INCUBATION 
CONDITIONS 
Sub-G0/G1 G0/G1 S G2/M 
FARAGE  
Control 1.33±0.33 54.67±1.67 31.67±5.18 7.67±3.18 
IWR-1 5 µM 7.00±1,53 61.33±1.76 25.33±4.84 14.00±2.52 
IWR-1 75 µM 13.00±0.00 
*** 
65.67±1.86 
** 
22.67±4.67 12.33±2.19 
10 µM 
vismodegib 
4.67±0.33 59.00±1.00 26.33±2.85 13.33±1.67 
57 µM 
vismodegib 
10.33±0.33 
*** 
70.33±0.33 
*** 
16.67±2.19 9.33±1.45 
 5 µM IWR-1 
+ 10 µM 
vismodegib 
7.00±1.53 64.67±1.76 24.33±0.33 9.33±2.33 
H929  
Control 2.67±0.88 64.33±0.88 32±0.58 3.67±0.89 
IWR-1 1 µM  4.00±1.00 65.67±2.03 $ 31.33±0.88 
$$$ 
3±1.16  
IWR-1 40 µM  4.33±1.20 73.00±0.58 
** 
22.67±0.67 
*** 
4.33±0.33 
vismodegib  
5 µM  
6.00±1.53 73.00±2.65 21.00±1.53 6.00±1.53 
vismodegib 
70 µM  
7.33±1.45 77.67±0.67 
*** 
12.33±0.33 
*** 
10.00±0.58 
** 
1 µM IWR-1 + 
5 µM 
vismodegib 
8.33±1.76 72.33±0.67 22.00±1.55 5.67±0.67 
Cells were incubated for 24 hours with IWR-1 and vismodegib inhibitors at the concentrations reported in the table. 
Subsequently, the different phases of the cell cycle were evaluated as described in the material and methods section. The results 
represent the mean ± SEM of three to four independent experiments, which are expressed as percentage (%) of cells at each stage 
of the cell cycle. * p<0.05; ** p<0.01; *** p<0.001, comparing with control; $ p<0.05; $$$ p<0.001 comparing with combination 
therapy. The statistical analysis was performed by comparison to control, using the ONE-WAY ANOVA. GDC, vismodegib 
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3.4 Inhibitors influence in proteins from the WNT/β-catenin and Hedgehog 
pathways 
When highly activated, WNT/β-catenin and Hedgehog signaling pathways induce an 
increase in β-catenin and ERK expression. To evaluate the mechanism of action of the 
inhibitors in study, IWR-1 and vismodegib, the expression levels of β-catenin and ERK were 
analyzed in H929 and Farage cells. This evaluation was conducted by flow cytometry, in 
presence and absence of the inhibitors in study as described in materials and methods 
section. 
Figure 23 represents the intracellular expression of β-catenin in H929 and Farage cells, 
expressed in mean fluorescence intensity (MFI). The results obtained were dependent on 
the cell line, drug and therapeutic scheme. In H929 cells (Figure 23A), 40 μM IWR-1 and 70 μM 
vismodegib (IC50 doses) induced a significant decrease in the β-catenin expression. However, 
the effect of the therapeutic combination of the two inhibitors was not statistically different 
from the one observed with the administration of the inhibitors individually (1 μM IWR-1 and 
5 μM vismodegib). In Farage cells (Figure 23B), β-catenin levels were decrease in cells treated 
with IWR-1 but the difference was not statistically significant. Besides that, H929 cells had a 
higher baseline level of β-catenin (2.25-fold, p=0.0017) than Farage cells. 
The intracellular expression of phosphorylated ERK (p-ERK) in H929 and Farage cells are also 
dependent on the cell line, drug and therapeutic scheme. As observed in Figure 24, H929 cells 
treated with 70 μM vismodegib show a statistically significant decrease in p-ERK expression 
compared with control. Although the difference is not significant, when H929 cells are treated 
with the combination scheme (1 μM IWR-1 + 5 μM vismodegib), a small decrease in p-ERK 
expression is also observed compared to control. In Farage cells, there are no statistically 
significant differences between the groups, despite the decrease in p-ERK expression in cells 
treated with all concentrations except 10 μM vismodegib. Similarly to that observed in H929 
cells, the therapeutic combination of IWR-1 and vismodegib did not show any benefit in 
decreasing p-ERK expression in Farage cells. 
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Figure 23 - Evaluation of intracellular expression of β-catenin in H929 and Farage cells treated with IWR-1 and 
vismodegib (GDC) by flow cytometry.  Intracellular expression of β-catenin in the absence and in the presence of IWR-
1 and vismodegib at the concentrations observed in the legend, was evaluated after 24 hours of incubation by flow 
cytometry, using monoclonal antibodies as described in materials and methods. The results are expressed as mean 
fluorescence intensity (MFI) and represent the mean ± SEM of three independent experiments. 40 µM IWR-1, 75 µM 
IWR-1,70 µM GDC, and 57 µM GDC correspond to IC50 doses for H929 and Farage cells. 1 µM IWR-1 + 5 µM GDC and 5 
µM IWR-1 + 10 µM GDC correspond to combination therapy doses for H929 and Farage cells. The statistical analysis 
was performed by comparison to control, using the ONE-WAY ANOVA. ** p <0.01. GDC, vismodegib 
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Figure 24 - Evaluation of intracellular expression of p-ERK in H929 and Farage cells treated with IWR-1 and 
vismodegib (GDC) by flow cytometry.  Intracellular expression of p-ERK in the absence and in the presence of IWR-1 
and vismodegib at the concentrations observed in the legend, was evaluated after 24 hours of incubation by flow 
cytometry, using monoclonal antibodies as described in materials and methods. The results are expressed as mean 
Fluorescence intensity and represent the mean ± SEM of three independent experiments. 40 µM IWR-1, 75 µM IWR-
1,70 µM GDC, and 57 µM GDC correspond to IC50 doses for H929 and Farage cells. 1 µM IWR-1 + 5 µM GDC and 5 µM 
IWR-1 + 10 µM GDC correspond to combination therapy doses for H929 and Farage cells. The statistical analysis was 
performed by comparison to control, using the ONE-WAY ANOVA.  ** p <0.01. GDC, vismodegib 
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4 Discussion  
Previous advances in the knowledge of the pathophysiology of multiple myeloma and 
diffuse large B-cell lymphoma have contributed decisively to improving the prognosis of these 
patients with these diseases. However, these advances were not yet sufficient. Detailed 
understanding of biological mechanisms involved in growth and maintenance of malignant cells 
in vivo is critical to improving or redirecting therapeutic strategies. Moreover, the knowledge 
of genetic, epigenetic, and mechanisms that overcome resistance to antineoplastic agents are 
also relevant. For this reason, apoptosis, cell cycle, inflammation, angiogenesis regulators, 
signaling pathways and the sensitivity of tumor cells to the immune response have all attracted 
attention, constituting therapeutic targets currently being evaluated.  
Multiple myeloma is characterized by a neoplastic clonal proliferation of plasma cells 
engaged in the production of a monoclonal immunoglobulin (143). These plasma cells 
proliferate in the bone marrow, producing extensive skeletal destruction that results in bone 
pain and fractures. MM patients are treated with standard therapy with dexamethasone 
associated with, lenalidomide and/ or bortezomib-based regimens (144,145). Despite the many 
therapeutic advances that have occurred in the last two decades in the MM, they are 
insufficient for the majority of patients, who die as a result of the progression of the MM. Thus, 
the search for drugs with innovative mechanisms of action, as well as the most effective 
combination with agents known to be active in this pathology are constant challenges for the 
scientific community. 
Diffuse large B-cell lymphoma is very heterogeneous at a clinical, pathologic, and molecular 
level. The standard treatment for DLBCL is R-CHOP (rituximab plus cyclophosphamide, 
doxorubicin, vincristine, and prednisone), which combines a therapeutic antibody with four 
chemotherapy drugs (146,147). Even with the addition of rituximab to the CHOP regimen, more 
than one-third of patients are refractory to or relapse after first line R-CHOP therapy, being 
their cure rate approximately 10% (148).  
 Major improvements in the treatment of diffuse large B-cell and multiple myeloma will 
include the incorporation of novel, rationally targeted agents into the standard treatment 
paradigm. A variety of intracellular oncogenic pathways can be potential targets for DLBCL and 
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MM therapy. Small molecules can selectively inhibit specific signaling molecules of critical 
pathways for survival  of lymphoma and myeloid cells (149). Since the differentiation pathways 
involving proteolytic receptors, such as WNT and Hedgehog (HH), may play a relevant role in 
the development of this type of B-cell neoplasms, they may be an excellent target for the 
treatment of these hematological malignancies. WNT/β-catenin signaling pathway plays an 
important role in the proliferation, differentiation and survival of hematopoietic cells. It has 
been shown that overexpression of WNT proteins would increase the proliferation of CD34+ 
cells and thus will be essential in the process of self-renewal of hematopoietic stem cells 
(150,151). Thus, due to the central function of the WNT pathway in hematopoiesis, the 
occurrence of some type of deregulation in this pathway increases the risk of hematological 
malignancies. Likewise, the Hedgehog pathway also plays a central role in hematopoiesis (90). 
In the adult hematopoietic system, HH signaling regulates the development of T cells, also 
functioning as a mechanism of survival in dendritic follicular cells, thus preventing apoptosis in 
germinal B cells. Thus, this work provide data that collectively supports the development, 
testing and possible future clinical use of WNT/β-catenin and Hedgehog inhibitors in the 
treatment of DLBCL, as well as in MM. 
Prior to this study, there are limited investigation using IWR-1 and Vismodegib in patients 
with MM and DLBCL and, according to clinical trial databases, clinical trials using the 
combination of drugs are also limited. Reviewing those databases, it is observed that some 
studies targeting the therapeutic potential of vismodegib are still ongoing (152). These trials 
tested the in vivo therapeutic potential of vismodegib in metastatic pancreatic cancer, ovarian 
cancer and basal cell carcinoma, among other neoplasms. Regarding hematological 
malignancies, one clinical trial is under study to test the possible use of vismodegib in patients 
with MM after autologous stem cell transplantation and recently it has terminated a phase II 
study with vismodegib in DLBCL patients (152). 
Considering these observations and despite the studies carried out with IWR-1, the  
WNT/β-catenin signaling pathway inhibitor, and vismodegib, the Hedgehog signaling pathway 
inhibitor, showed good results in several types of cancer, their therapeutic efficacy in 
hematological malignancies is still not well understood. Thus, the main objective of the present 
study was to evaluate the therapeutic potential of these WNT and Hedgehog signaling 
pathways inhibitors in the modulation of apoptosis response in multiple myeloma and diffuse 
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large B-cell lymphoma. Furthermore, considering that one of the most promising strategies in 
the treatment of hematological malignancies pathology is related to the combined action of 
several drugs, the therapeutic potential of IWR-1 and vismodegib in MM and DLBCL was also 
evaluated in combination therapy. 
In this study IWR-1 and vismodegib decreased the metabolic activity in both MM and DLBCL 
cells in a dose- and cell type- dependent manner, inducing cell death preferentially by apoptosis 
(Figures 11, 12 and 17). Results demonstrate that the administration of higher doses of IWR-1 
and vismodegib, in both H929 and Farage cells, decreases more significantly its cells metabolic 
activity and induces a time of exposure-dependent effect.  However, the effect induced in H929 
cells by IWR-1 is obtained earlier with lower concentration (IC50 of 40 μM) than in Farage cells 
(IC50 of 75 μM). In contrast, Farage cells have an early response to vismodegib, with an IC50 of  
57 μM and 70 μM respectively, at 24h of incubation. Despite this early response in Farage cells 
incubated with vismodegib, these cell present only a dose-dependent effect while H929 cells 
incubated with vismodegib have a dose- and time- dependent effect.  
The observed decrease in metabolic activity induced by inhibition of WNT/β-catenin 
pathway with IWR-1 in H929 and Farage cells was expected, due to the increased activation of 
this pathway in MM and DLBCL, showed in previous studies. According to Raphael Koch and 
collaborators (2014), homeostasis in DLBCL  depends on WNT signaling within and between 
neoplasia cells (153). Also, Ge X, and colleagues, (2012) showed that the increase of the nuclear 
β-catenin protein, a marker of WNT pathway activation detected in some DLBCL tumors, 
correlates with poor outcome (76). This means that preventing WNT signaling in this context 
results in decreased cell growth and decrease in cell colony formation. Some authors showed 
that the increased abundance of B cell lymphoma 9 (BCL9), which activates β-catenin, 
contributes to the increased activation of WNT pathway in MM (154,155). Furthermore, a small 
molecule inhibitor of the BCL9-β-catenin interaction blocks multiple myeloma cell growth 
(154). Although, various studies suggest the increase of WNT signaling in at least a subset of 
DLBCL patients, the impact of WNT signaling in lymphoma is less understood (55, 76, 153,156).  
WNT/β-catenin inhibitor, IWR-1, has already demonstrated a significant antitumor effect in 
colorectal cancer and in lung cancer, as well as in some hematological tumors such as mantle 
cell lymphoma (157–159). In the present study, the concentration of IWR-1 required to achieve 
IC50 in H929 and Farage cells was much higher than that previously reported, confirming once 
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again that the effect of this drug, besides being dose and time-dependent, also depends on the 
cell type.  
In addition to the signaling pathway mentioned before, Hedgehog signaling pathway is also 
involved in the regulation of normal development and oncogenesis of various tissue types 
(102,117). Previously it has been reported that abnormal activity of the Hedgehog signaling 
pathway can lead to tumorigenesis during adult life (160). Mainly, it is the microenvironmental  
cells  and  supportive  stroma  of  the  bone marrow and lymphoid organs that produce the HH 
ligand, which is required  for  lymphoid  cell  maintenance (161). However, constituents and 
targets of HH signaling are expressed in various lymphoma cell lines and primary tissue 
(110,162). IHH and SHH have been shown to be survival factors in B-cell malignancies, such as 
DLBCL (110). Also, several studies demonstrate a specific involvement of HH signaling in 
hematologic malignancies, not only in supporting cancer stem cells but also in promoting 
growth and survival of mature malignant cells (91,163–166). Other studies show that the HH 
pathway inhibition induces apoptosis and reduces drug resistance in human acute myeloid and 
lymphoid leukemia (167–169). According to Desh P. et al (2010), SMO-dependent as well SMO-
independent HH activation support B-cell chronic lymphocytic leukemia (B-CLL) cell survival, 
correlates with adverse indicators of clinical outcome, and GLI1 inhibition increases 
susceptibility to fludarabine-induced cytotoxicity (170,171). Altogether, these results indicate 
that molecular targeting of HH pathway is a potential therapeutic approach to improve 
treatment of hematologic malignancies. The results obtained in this work demonstrate that a 
SMO protein antagonist, vismodegib, decreased the metabolic activity in H929 and Farage cells, 
as expected, with an IC50 of 70 μM and 57 μM for H929 and Farage cells, respectively, at 24h of 
incubation. 
Simona Blotta et al. (2012) observed that CD138+ MM cells express HH genes and confirmed 
SMO–dependent HH signaling in MM using a synthetic SMO inhibitor, NVP-LDE225, which 
decreased MM cell viability by inducing specific down-regulation of GLI1 and PTCH1, two 
hallmarks of HH activity (116). Another study evidenced the contribution of GLI1 protein in the 
survival of DLBCL cells (118). These authors demonstrated that GLI1 contributes to cell survival 
of DLBCL cells through the expression of AKT, and the same mechanism may also occur in other 
malignant tumors. Thus, the use of Hedgehog pathway inhibitors, notably vismodegib, may be 
a promising therapeutic approach for patients, as can be observed in the results of this work, 
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either alone or in combination with other modulators of other signaling pathways. Thus, due 
to this increased activation of Hedgehog pathway in MM and DLBCL, the observed decrease in 
metabolic activity induced by vismodegib in H929 and Farage cells was expected. 
Previously, vismodegib, had showed significant clinical efficacy against HH-driven 
malignancies, such as advanced or metastatic basal cell carcinoma and medulloblastoma (>50% 
response)  (132,172). However, the concentration of vismodegib required to achieve IC50 in 
H929 cells and in Farage cells was different, suggesting once again that the effect of this drug, 
besides being dose- and time-dependent, is also dependent on the cell type.  
The present study suggests that H929 cells are more sensitive to IWR-1 and to vismodegib 
compared to Farage cells. In fact, it was found that this inhibitor exerts a superior effect for the 
same concentration on H929 cells relative to Farage cells, translating in a higher reduction on 
cellular metabolic activity, using lower doses. Although, Farage cells present an earlier response 
to vismodegib compared to H929 cells. Accordingly, H929 cells treated with a WNT/β-catenin 
pathway inhibitor, IWR-1, showed a decrease in β-catenin expression (Figure 23), and, in Farage 
cells treated with the same inhibitor, the reduction in β-catenin expression was not significant. 
Independently of the effect in β-catenin, IWR-1 still induced cell death in Farage cells, which 
could indicate an alternative mechanism of action of IWR-1 in these cells. Moreover, H929 cells 
expressed a higher baseline level of β-catenin expression (2.25-fold) than Farage cells, which 
may be a reason for the better response to IWR-1 observed in H929 cells. In previous studies, 
MM and DLBCL patient samples showed an increase in β-catenin expression due to the 
aberrant activation of WNT/β-catenin signaling pathway, as well as a preferential nuclear 
localization of β-catenin (76,173). Decreased β-catenin expression in treated H929 cells is in 
agreement with various papers in which IWR-1 or JW74, an inhibitor similar to IWR-1, strongly 
reduced nuclear levels of total β-catenin and active β-catenin in a dose-dependent manner 
(123,174). However, the role of β-catenin in normal and malignant hematopoietic cells has not 
yet been properly evaluated. Some authors evaluated several leukemic cell lines and suggest 
that β-catenin regulates adhesion, proliferation, and survival in these leukemic cells (175). 
Constitutively activated β-catenin signaling, due to APC deficiency or β-catenin mutations that 
prevent its degradation, leads to excessive stem cell renewal and/or proliferation. In turn, this 
predisposes cells to tumorigenesis (176).  Therefore, the use of protein stabilizers, namely IWR-
1, increases levels of axin, inducing a decrease in free β-catenin levels and, therefore, the arrest 
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of activation of the target genes and subsequent activation of this signaling pathway (121). 
Thus, the use of WNT/β-catenin inhibitors, notably IWR-1, may be a good therapeutic approach 
for MM and DLBCL patients, either in monotherapy or in combination with other modulators 
of this signaling pathway.  
Vismodegib, the Hedgehog signaling pathway inhibitor, also induced a decrease in  
β-catenin expression in both H929 and Farage cells. This could indicate a possible link between 
WNT/β-catenin and Hedgehog pathways. This crosstalk between the WNT and HH pathways, 
may occur through a mechanism involving the endogenous WNT-inhibitory factor secreted 
frizzled related protein 1 (sFRP-1), which is induced by the HH pathway transcription factor GLI1 
in gastric cancer cell lines (177). Specifically, it has been reported that HH signaling inhibits WNT 
signaling pathway upregulation of sFRP-1 and suppresses β-catenin transcriptional activity 
(177,178). Additionally, further accentuating this crosstalk, in medulloblastoma cells, inhibition 
of WNT signaling was able to reduce the propagation and growth of SHH-subgroup 
medulloblastoma in vivo, in an on-target manner, leading to increased cell survival (179).  
In the present work, it was also evaluated whether the mode of administration of the 
modulators of WNT/β-catenin and Hedgehog pathways could influence the effect on the 
metabolic activity of the cells in study. Thus, it was observed that IWR-1 has a more pronounced 
effect when they were administrated daily at low concentrations than when the same dose 
concentration is administered in a single dose in H929 and Farage cells. In vismodegib 
administration, it was observed that it has a more pronounced effect when they were 
administrated daily at low concentrations than when the same dose concentration is 
administered in a single dose, but only in H929 cells. Farage cells did not show a benefit in daily 
administration of vismodegib contrarily to what was expected due to its higher sensibility to 
vismodegib than H929 cells. This therapeutic scheme, which mimics the administration of most 
anticancer drugs used in clinical practice, may allow the therapeutic use of these compounds 
with a minimum of systemic secondary toxic effects. However, it has to be taken into account 
that the biological mechanisms underlying this scheme of administration have not been 
studied. In both administration methods, daily or a single dose, the greatest reduction in 
cellular metabolic activity occurred after the first 24 hours of exposure, showing a rapid 
antiproliferative effect (Figures 13 and 14).  
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Additionally to the daily administration of IWR-1 and vismodegib, the effect of the 
combination of the two drugs was also studied. In H929 cells, the therapeutic association  
(5 μM vismodegib and 1 μM IWR-1) showed an accumulative effect compared to the 
administration of the two drugs alone (Figure 15). However, for Farage cells, the increase in 
effectiveness is much more remarkable, once the association of IWR-1 with vismodegib 
resulted in a synergistic effect when compared to monotherapy. It will be of interest to further 
assess in the future whether there is also a potentiation of the side effects of the two drugs 
with that association, in comparison with the safety profile of the monotherapy. These results 
indicate that a combination therapy may bring benefits to the patient, since the administered 
concentrations of each drug are lower than those administrated as a single dose. Therefore, 
this therapeutic scheme may be a good option in the treatment of MM and DLBCL, aiming to 
increase the quality of life of these patients and decrease the therapeutic side effects. In the 
next future, the combination of these new biological drugs with conventional chemo and/or 
immunotherapy should be tested, and, if favorable, incorporated in the first-line management 
of MM and DLBCL patients in attempt to increase the response rate and cancer-free survival. 
To study the cytotoxic effect of both drugs and some of the mechanisms involved, cell death 
was analyzed by Flow Cytometry through double cell labeling with Annexin V and  
7-AAD, as well as by the analysis of Caspases and BCL2 expression. WNT signaling activates Dvl 
to inhibit GSK-3β activity, resulting in the stabilization of β-catenin and the activation of  
β-catenin/Tcf–mediated transcription. Thus, β-catenin stabilization, as well as the formation of 
a complex with Tcf transcription factors, is likely to play a critical role in WNT-mediated  
anti-apoptosis. IWR-1 suppresses WNT signaling by stabilizing the axin destruction complex 
(123). Thus, by inhibiting WNT/β-catenin pathway using IWR-1, it is expected to observe an 
increase in apoptosis, which was confirmed in this study in H929 and Farage cells treated with 
IWR-1 (Figure 17). Accordingly, an increase in activated caspases expression (pro-apoptotic 
molecules) is observed in both cell lines, as well as a slight decrease in BCL2 expression 
 (anti-apoptotic molecules) in Farage cells. Furthermore, morphologic analysis of treated cells 
with IWR-1 demonstrated typical morphological characteristics of apoptosis, in a more initial 
phase, with cytoplasmic projections (blebs) and vacuolization, and cells with nuclear 
contraction and fragmentation, typical characteristics of more advanced stages of cell death by 
apoptosis (Figure 18 and 19). These results confirm apoptosis as the cell death mechanism 
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induced by IWR-1 in H929 and Farage cells. The same is observed when cells were treated with 
vismodegib, in accordance with previous studies that showed that this drug inhibits cell viability 
and induces apoptosis in various cancerous cells (180,181). According to Brahma S. and 
colleagues (2011), vismodegib induced apoptosis through caspase-3 activation, Poly  
(ADP-ribose) polymerase (PARP) cleavage,  increased Fas expression, and BCL2  
down-regulation in cancer stem cells (CSC) (181). In other study, with the intervention of 
vismodegib in basal cell carcinoma, the anti-apoptotic gene BCL2 was downregulated at the 
mRNA and protein level, which was in parallel with an increase in cell apoptosis observed by 
flow cytometry (182). Thus, the obtained results confirm that apoptosis was the main 
mechanism involved in cell death, since a significant activation of caspases was observed in 
both H929 and Farage cells (Figure 20 and 21). However, regarding BCL2 expression, only 
Farage cells showed a significant decrease in its expression (Figure 22). These results are in 
agreement with the results obtained by the other methods used in this study to analyze the 
type of cell death, like morphologic analysis of the cells which showed cytoplasmic projections 
(blebs), vacuolization, nuclear contraction, and fragmentation, typical characteristics of cell 
death by apoptosis, as mentioned. 
In this work, in addition to the observed cytotoxic effect, IWR-1 and vismodegib induced an 
antiproliferative effect on cells, which was confirmed by cell cycle analysis performed by Flow 
Cytometry. WNT/β-catenin signaling pathway is well known for its close relationship with cell 
proliferation and cell apoptosis (183). Cyclin D1, the gene in the downstream of WNT/β-catenin 
signaling pathway, is intimately related with cell cycle. This cell cycle regulator plays a leading 
role at G1 phase and regulates the entry of cells into the S phase of the cell cycle (183). In other 
study, epithelial cells with high glucose treated with IWR-1 also had an arrest in the same 
phases of the cell cycle (184). Accordingly, in the present study, H929 and Farage cells exposed 
to IWR-1 showed cell cycle arrest in G0/G1 phase of the cell cycle, probably on G1 phase, based 
on the previous mentioned studies. Relating to HH pathway, it has been reported that 
Hedgehog controls the cell cycle in a variety of circumstances (185). This signaling pathway may 
influence directly and operate through interaction with cell cycle regulators at multiple points 
within the cell cycle (186). Several authors showed that by inhibition of Hedgehog signaling 
results in cell cycle arrest in G0/G1 phases (110,187).  Onishi H. et al. (2013) reported that 
cyclopamine, an HH inhibitor similar to vismodegib, induced cell cycle arrest in G0/G1 in treated 
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T and NK lymphocytes (187). The same was observed in small cell lung cancer (188). In the 
present work, H929 and Farage cells exposed to vismodegib showed cell cycle arrest in the 
G0/G1 phase of the cell cycle, similarly to those treated with IWR-1.  In Farage cells, a sub-G1 
peak was also observed in cells treated with IWR-1 and vismodegib in monotherapy. This sub-
G1 peak is characteristic of cells in apoptosis and confirms once again the induction of this type 
of cell death. Combination therapy with IWR-1 and vismodegib, did not demonstrate a 
significant antiproliferative effect.  
The extracellular-signal-regulated kinase (ERK) pathway is one of the major signaling 
cassettes of the mitogen activated protein kinase (MAPK) signaling pathway (189). This ERK 
pathway contributes to the regulation of cell proliferation, phosphorylation of the transcription 
factor p53, among others (190). p-ERK is the phosphorylated and activated form of ERK. ERK 
expression has been demonstrated to be increased in DLBCL and most MM patients (191–193). 
In the present work, neither H929 or Farage cells treated with IWR-1 and vismodegib, in 
monotherapy or combination therapy, showed a significant reduction in p-ERK expression, 
except for H929 cells treated with 70 µM vismodegib (Figure 24). In the latter, there is a 
significant reduction in p-ERK expression. Kasper M et al. (2006) have demonstrated that 
coexpression of the GLI/EGF activate ERK1/2 in human hair follicles (194). This can mean that 
activation of Hedgehog signaling contributes to a high expression of GLI proteins and, 
consequently, a high expression of ERK. Thus, a reduction in p-ERK expression is expected, 
when using a Hedgehog inhibitor. EGFR/MEK/ERK signaling induces JUN/activator protein 1 
activation, which is essential for oncogenic transformation, in combination with the GLI 
activator forms GLI1 and GLI2 (195). This suggests that a combination therapy of vismodegib, 
Hedgehog pathway inhibitor, and a MEK/ERK inhibitor may be an interesting therapeutic 
approach to study in the future. In other hand, it has been demonstrated a link between ERK 
and WNT/β-catenin pathways, in which both pathways are activated by WNT3a (196). This 
suggests that an aberrant WNT/β-catenin activation translates in an increase in ERK expression. 
Thus, by inhibiting WNT/β-catenin pathway, a decreased of p-ERK is expected. The link 
between p-ERK and the two signaling pathways in study is very indirect which may be a 
justification for the absence of response on p-ERK expression in H929 and Farage cells treated 
with IWR-1 and vismodegib. 
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In sum, it can be concluded that drugs which aim at molecular targets of the signaling 
pathways, such as IWR-1 and vismodegib, may be considered promising therapeutic 
approaches in B-cell neoplasms, namely MM and DLBCL, both in monotherapy and in 
combination therapy. Although preclinical studies of IWR-1 and vismodegib inhibitors in MM 
and DLBCL have demonstrated a capacity to induce malignant cells apoptosis, solid tumor 
studies indicate that the therapeutic benefit of these inhibitors alone are likely to be of limited 
benefit. Therefore, future clinical approaches require a shift towards using signaling pathway 
inhibitors in combination with current anti-MM and DLBCL compounds and other novel small 
molecule inhibitors. 
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2. Conclusion  
The development of new therapeutic strategies for the treatment of cancer constitutes the 
focal point of investigation on oncology nowadays. The study of the influence and therapeutic 
potential of the cell differentiation pathways, WNT/β-catenin and Hedgehog, in multiple 
myeloma and diffuse large B-cell lymphoma, concluded that IWR-1 and vismodegib have 
cytotoxic and cytostatic effects on H929 and Farage cells, both in monotherapy and in 
combination therapy. Thus, these results revealed that IWR-1 and vismodegib may be 
promising therapeutic strategies in MM and DLBCL treatment. 
The cytotoxic effects induced by IWR-1 and vismodegib on H929 and Farage cells were 
dependent on time, concentration, drug administration scheme, and cell line type. Thus, it is 
found that H929 cells are more sensitive to treatment with IWR-1 and vismodegib, whereas 
Farage cells have been shown to have an early response to treatment with vismodegib. 
In addition, it was observed that the daily administration of IWR-1 and vismodegib at lower 
concentrations would be beneficial and could undermine toxicity and side effects in both H929 
and Farage cells. Daily administration showed a better efficacy in H929 cells, compared with 
one single administration of the total dose. It should also be noted that the combined therapy 
of these compounds showed to be quite efficient in the reduction of cell proliferation and may 
be a good starting point for a future therapeutic approach, especially in Farage cells. 
Further studies performed with the WNT/ β-catenin and HH pathway inhibitors suggest that 
these inhibitors induce cell death mainly by apoptosis. This fact was evidenced by the increase 
in caspase levels and by morphologic analysis of the cells. In Farage cells, the appearance of an 
apoptotic peak (sub-G0/G1), corroborates death by apoptosis. Moreover, inhibition of  
WNT/β-catenin pathway by IWR-1 decreased β-catenin expression in H929 cells. However, this 
effect cannot be observed in Farage cells.  
In summary, IWR-1 and vismodegib can be an effective therapy, in association and in single 
dose administration, in the treatment of MM and DLBCL. However, for the validation of the 
results, it is necessary to enlarge the number of MM and DLBCL cell lines used in order to mimic 
the large diversity and heterogeneity of the diseases. The study of combination therapy of  
IWR-1 and Vismodegib with conventional therapeutics like bortezomib and rituximab should 
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also be done. It is also important to deepen the study of the signaling pathways in the 
pathophysiology of Multiple myeloma and diffuse large B cell lymphoma. Thus, it should be 
added that there is still much work to be done in order to study the influence of these signaling 
pathways on hematological malignancies. Nonetheless, this work has demonstrated a good 
starting point for a very attractive and innovative project, which could bear promising results 
in the future, particularly for the treatment of patients with Multiple Myeloma and Diffuse 
Large B-cell Lymphoma. 
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